An immunoPET probe to SARS-CoV-2 reveals early infection of the male genital tract in rhesus macaques

Patrick J. Madden[1], Yanique Thomas[1], Robert V. Blair[2], Sadia Samer[1], Mark Doyle[2], Cecily C. Midkiff[2], Lara A. Doyle-Meyers[2], Mark E. Becker[1], Muhammad S. Arif[1], Michael D. McRaven[1], Lacy M. Simons[3, 4], Ann M. Carias[1], Elena Martinelli[1], Ramon Lorenzo-Redondo[3, 4], Judd F Hultquist[3, 4], Francois J. Villinger[5], Ronald S. Veazey[2], and Thomas J. Hope[1*]

[1]Department of Cell and Developmental Biology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA.

[2]Tulane National Primate Research Center, Covington, Louisiana, USA.

[3]Department of Medicine, Division of Infectious Diseases, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.

[4]Center for Pathogen Genomics and Microbial Evolution, Havey Institute for Global Health, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.

[5]New Iberia Research Center, University of Louisiana-Lafayette, New Iberia, Louisiana, USA.

PET/CT detected SARS-CoV-2 infection of 4 different tissues in the male genital tract illuminates the cause of COVID-19 clinical sequalae of male sexual health and fertility

Prostate
- Increased PSA
- Decreased semen quality

Penis
- Erectile Dysfunction
- Peyronie's Disease

Pampiniform Plexus
- Thrombosis
- Testicular pain
- Testicular atrophy

Testis
- Decreased sperm count
- Decreased semen quality
- Decreased testosterone
- Decreased fertility
- Testicular pain
- Orchitis

Graphic Abstract

17   **Graphic Abstract Legend: Diagram shows schematic illustration of the male genital tract of**

18   **the rhesus macaque. Virus icon shows sites of SARS-CoV-2 PET signal. Text highlighting the**

19   **clinical sequalae associated with each sight of infection is shown in text adjacent to each**

20   **infection site.**

21

Abstract

The systemic nature of SARS-CoV-2 infection is highly recognized, but poorly characterized. A non-invasive and unbiased method is needed to clarify whole body spatiotemporal dynamics of SARS-CoV-2 infection after transmission. We recently developed a probe based on the anti-SARS-CoV-2 spike antibody CR3022 to study SARS-CoV-2 pathogenesis *in vivo*. Herein, we describe its use in immunoPET to investigate SARS-CoV-2 infection of three rhesus macaques. Using PET/CT imaging of macaques at different times post-SARS-CoV-2 inoculation, we track the ^{64}Cu-labelled CR3022-F(ab')2 probe targeting the spike protein of SARS-CoV-2 to study the dynamics of infection within the respiratory tract and uncover novel sites of infection. Using this method, we uncovered differences in lung pathology between infection with the WA1 isolate and the delta variant, which were readily corroborated through computed tomography scans. The ^{64}Cu-CR3022-probe also demonstrated dynamic changes occurring between 1- and 2-weeks post-infection. Remarkably, a robust signal was seen in the male genital tract (MGT) of all three animals studied. Infection of the MGT was validated by immunofluorescence imaging of infected cells in the testicular and penile tissue and severe pathology was observed in the testes of one animal at 2-weeks post-infection. The results presented here underscore the utility of using immunoPET to study the dynamics of SARS-CoV-2 infection to understand its pathogenicity and discover new anatomical sites of viral replication. We provide direct evidence for SARS-CoV-2 infection of the MGT in rhesus macaques revealing the possible pathologic outcomes of viral replication at these sites.

42   **Introduction**

43   The COVID-19 pandemic has exposed the broad systemic impact that can be caused by

44   infection with a respiratory virus. Disease associated with SARS-CoV-2 infection starts with

45   respiratory pathologies and subsequently can extend to other organ systems. There is now

46   ample evidence that SARS-CoV-2 can disseminate and replicate in tissues beyond the

47   respiratory tract. A clear example is infection in the gastrointestinal (GI) tract[1]. GI symptoms,

48   including diarrhea, have been reported by individuals with mild COVID-19, and hospitalized

49   patients have exhibited more severe symptoms such as ischemia and GI bleeds [2, 3,4]. In addition,

50   it is now well established that virus is shed through the GI tract in most infected individuals and

51   wastewater screening has become an important tool for disease surveillance[5, 6]. Although less

52   studied, many other tissues have been found to harbor SARS-CoV-2. Multiple groups have

53   shown the presence of viral RNA in cardiac, renal, and brain tissues[7-10]. There is also some

54   evidence of virus in the male genital tract (MGT) [11, 12]. Furthermore, symptoms associated with

55   all these organ systems have been regularly reported[13]. Likewise, other RNA viruses have

56   documented early dissemination to distal tissues that manifest infection-related pathology over

57   the long term, including (but not limited to) polio, mumps, Ebola virus, Zika virus, and SARS-

58   CoV-1[14, 15]. For example, studies of autopsy tissue from fatalities of SARS-CoV-1 suggested that

59   it causes inflammation of the testes (orchitis)[15].

60   However, it is not yet clear if the diverse pathologies associated with SARS-CoV-2

61   infection are due to secondary effects of systemic inflammation or direct infection of tissues at

62   these distal sites. Human studies have relied on biopsies and autopsy samples to investigate

63   viral replication in sites other than the respiratory tract. The biopsy/autopsy samples only offer

4

64   a snapshot of the *in vivo* dynamics of disease, and there are ethical and technical difficulties in

65   obtaining them. Using animal models of infection allows for a more thorough collection and

66   investigation of affected tissues. To gain critical insights into systemic infection by SARS-CoV-2,

67   new animal models are needed to determine the extent of disseminated infection and its

68   relationship to pathogenesis.

69   SARS-CoV-2 infection in the non-human primate (NHP), rhesus macaques (*Macaca*

70   *mulatta*), recapitulates mild to moderate human disease[16-18]. Infected macaques exhibit viral

71   shedding through the respiratory tract and viral pneumonia similar to the mild form seen in

72   humans. The architecture of the respiratory tract is also generally conserved between humans

73   and macaques making them an ideal model for studying SARS-CoV-2 infection. Infection of

74   other organ systems has also been observed in macaques, most commonly in the GI tract[19, 20].

75   To gain insights into the spatiotemporal dynamics of SARS-CoV-2 during infection in the rhesus

76   macaque model, we adapted an immunoPET methodology that we are currently using to study

77   various aspects of simian immunodeficiency virus (SIV) acquisition and pathogenesis[21].

78   ImmunoPET is a molecular imaging technique that combines the specificity of an antibody-

79   based probe labeled with a radioisotope with the *in vivo* imaging power of combined positron

80   emission tomography-computed tomography (PET/CT). ImmunoPET was originally developed

81   and has been widely used in cancer research. Recently, with the advent of new antibodies and

82   better radioisotopes, immunoPET has been extended to studying many other biological

83   processes, including the *in vivo* dynamics of pathogens [22, 23]. ImmunoPET allows for repeated

84   and specific imaging of virally infected cells *in vivo* by using a radioisotope labeled antibody

85   targeting a viral protein. The non-invasive nature of PET/CT imaging allows for unbiased

86   discovery of novel tissue sites of infection through whole body imaging. Furthermore, the cell-

87   associated PET signal persists in tissue allowing for a radioactive probe-guided necropsy to help

88   determine the precise location of infected cells.

89   We have previously reported the early development of an *in vivo* antibody-based probe

90   against SARS-CoV-2 utilizing fluorescent tagging of the F(ab')2 of the anti-spike IgG CR3022[24].

91   CR3022 was one of the first monoclonal antibodies identified that bound tightly to SARS-CoV-2.

92   It was originally derived from an individual infected with SARS-CoV-1 but also exhibits tight

93   binding to the spike protein of SARS-CoV-2. Here, we extend the use of the F(ab')2 of the anti-

94   spike IgG CR3022 labelled with copper 64 (Cu^{64}) for immunoPET and targeted necropsy to study

95   systemic SARS-CoV-2 infection in the rhesus macaque model. Our results show the utility of this

96   approach in investigating SARS-CoV-2 pathogenesis in the respiratory tract and in uncovering

97   novel anatomical sites of infection. Interestingly, we detected a robust and dynamic signal in

98   the MGT including the prostate, penis, and testicles. This observation is consistent with

99   emerging and ongoing clinical observations of orchitis, oligo-/azoospermia, and erectile

100   dysfunction, and reveals these comorbidities are likely a consequence of the direct viral

101   infection of the tissues of the MGT. The successful development of an immunoPET probe to

102   study SARS-CoV-2 in the rhesus macaque challenge model will allow longitudinal studies to gain

103   insights into SARS-CoV-2 progression, dissemination, and the development of comorbidities.

104

105   **Results**

106   **Description of macaque studies and PET/CT-guided necropsy**

107   The basic process and workflow of the PET/CT guided necropsy method is shown in Fig 1A. The

108   PET/CT guided necropsy approach consists of three separate PET/CT scans that are used to map

109   probe signal at the whole animal, organ, and tissue levels. The first scan is typically ~16-24

110   hours after the injection of the radio labelled F(ab')2 probe allowing for movement into the

111   tissues[21]. This whole-body PET/CT scan (Scan 1) identifies "hot" organs and tissue areas. These

112   tissue areas are collected at necropsy immediately following the scan and subjected to a second

113   PET/CT scan (Scan 2). Tissues containing probe signal are cut into small blocks, placed in

114   cryomolds, and then rescanned (Scan 3) to identify individual "hot" tissues/blocks that likely

115   contain foci of virally infected cells. These "hot" tissues can then be used for downstream

116   characterization including RNA quantification and different types of microscopic analyses

117   characterizing virally infected cells.

118   The SARS-CoV-2 pilot infection study design with 3 male rhesus macaques is shown in

119   Fig 1B. Based on our previous studies utilizing a fluorescently tagged F(ab')2 probe, we decided

120   to perform the first PET/CT scan 1 week after challenge. In the first study, we infected a male

121   rhesus macaque (LP14) with the WA1 isolate of SARS-CoV-2 and performed a single PET/CT

122   scan followed immediately by necropsy. In the second study, two male rhesus macaques were

123   infected with the Delta variant of SARS-CoV-2, and both underwent a PET/CT scan 1 week after

124   infection. One of the animals (IN22) was scanned twice after a single probe injection and

125   necropsied after the 2nd scan. The early scan of IN22 was done 3 hours after injection of the

126   ^{64}Cu-labelled F(ab')2 probe and a second whole-body scan was done ~21 hours after probe

127   injection with the PET/CT guided necropsy done immediately after. For the third animal (JF82),

128   the 1st PET/CT scan at week 1 post infection was performed ~22 hours after IV probe

7

129 administration. On day 13, this same animal, JF82, was evaluated at week 2 post-infection by

130 whole-body scan 18 hours after probe administration followed by necropsy and subsequent

131 scans.

132

133 **SARS-CoV-2 infection characteristics**

134 SARS-CoV-2 infection of the 3 animals was monitored via classical hematoxylin and eosin

135 (H&E) staining for evaluation of lesions in lung tissue (Fig 1C-E) and via quantification of

136 genomic and subgenomic RNA in nasal swabs and saliva (Fig 1F, G). Pathology varied from

137 minimal in LP14 (Fig 1C), to mild in IN22 (Fig 1D) and JF82 (Fig 1E). These findings are consistent

138 with the pulmonary pathology of SARS-CoV-2 infected rhesus macaques observed in other

139 studies performed at the Tulane National Primate Research Center[17, 25]. The pulmonary

140 pathology consisted of variable interstitial inflammation and type II pneumocyte hyperplasia

141 (IN22 and JF82), which in the most severely affected animal (IN22) also exhibited prominent

142 atypia. Fig 1F and G shows the level of genomic (Fig 1F) and subgenomic (Fig 1G) RNA in nasal

143 swabs and saliva for all 3 animals. No obvious differences were noted in viral loads between the

144 3 animals.

145

146 **Distribution of SARS-CoV-2 signal after 1 week of infection with the WA1 isolate**

147 The three PET/CT scans of LP14, including the whole body (Fig 2A and B, S1-video), the organ

148 scan (Fig 2C, D, and E, S2-video) and the tissue scan (Fig 2F), revealed probe signal at a number

149 of distinct anatomical sites. As expected, there was a strong signal in the kidneys, which is a

150 consequence of the excretion of the radiolabeled probe. To better evaluate the probe signal in

8

151   the lungs, the 3D reconstruction of the lungs was isolated from the PET datasets, and the lung

152   signal was projected over the CT reconstruction of the skeleton (Fig 2G and H, S3-video). The

153   signal associated with the lungs was diffuse and quite uniform throughout the tissue as

154   observed in the whole animal scan. This is more evident in the projection of the lung signal

155   without CT (Fig 2I and J, S3-video). However, the lung signal was more evident in the post

156   necropsy organ scan when the intact respiratory tract including the tongue were scanned again

157   (Fig 2C). In this case, lungs were no longer inflated within the body increasing signal density,

158   leading to higher signal in the 2nd scan. Two different respiratory tract z-series images (Fig 2K

159   and L) reveal a focus of signal associated with the base of the tongue, overlapping with the

160   pharynx as evidenced by the cartilaginous structures seen in the CT. There were abundant small

161   foci of signal distributed throughout the lung tissue, often adjacent to the trachea and bronchi

162   as they branch out into the lungs. In addition, the z-series' reveal that the observed PET signal is

163   associated with the tissues and not with the open airways of the bronchus and ever narrowing

164   bronchi. Immunofluorescence microscopy revealed areas of infected cells lining alveoli in lung

165   tissue sections that had PET/CT signal (Fig 2M and N) confirming the specificity of the PET

166   signal.

167   In contrast to the weak, diffuse signal associated with the lungs, there was a strong and

168   more focal PET signal within the MGT as shown in the front (Fig 3A) and side (Fig 3B-C) views

169   (S4-video). The testes have a generally diffuse signal with some concentration of signal at the

170   dorsal and ventral surface of both LP14 testes. The MGT of the rhesus macaque is similar to

171   that of humans but is distinct in several ways. Most notably, it is primarily retracted within the

172   body covered by a prepuce with a small bone located within the glans penis known as the

9

173   baculum (visible in the CT scan of the animals, Fig 3B and C, red arrow). There was a very

174   pronounced PET signal associated with the root of the penile tissues, which is buried within the

175   abdomen. The 3D PET signal was projected in green in a front (Fig 3D) and side view (Fig 3E) to

176   better illustrate the signal associated with the MGT and to visualize the signal from the root of

177   the penis (see S5-video). The localization of the PET signal for the penis and testes in the

178   context of the skeletal CT signal is shown in three different projections in panels 3F, 3H, and 3J,

179   and isolated in panels 3G, 3I, and 3K (S6-video). The testis overlays shown in Fig 3L-O reveal

180   that the PET signal is primarily associated with the testis and is distributed throughout the

181   testicular tissue. There is also some potential signal associated with the epididymis.

182   In anticipation of a potential signal in the testes, which are known to express the SARS-

183   CoV-2 receptor ACE2, we had designated the testes to be a component of the organ scan post

184   necropsy. Unfortunately, much of the penis tissue was discarded at the necropsy of LP14,

185   though we were able to isolate a small piece of penile tissue remaining within the abdomen.

186   This small piece of penile tissue retained PET signal as can be seen in Fig 2 (Fig 2F: row 8 column

187   5, Fig S2). To potentially identify infected cells within the testicular tissue of LP14, we evaluated

188   tissue sections for expression of SARS-CoV-2 proteins and host proteins using

189   immunofluorescence microscopy. In LP14, we found that ACE2 is expressed in the peritubular

190   myoid and Sertoli cells surrounding/lining the base of the seminiferous tubules (Fig 4A). Next,

191   we stained testicular tissue sections from LP14 with an anti-SARS-CoV-2 guinea pig serum.

192   Infected cells were evident in seminiferous tubules but were not widely distributed and were

193   instead localized in small clusters of cells at the base of the seminiferous tubules (Fig 4B).

194   Infection of Leydig and other interstitial cells could not be evaluated due to loss of these cells

195   during tissue processing. To further investigate the phenotype of infected cells, we stained with

196   markers to help identify peritubular myoid cells (smooth muscle actin) and Sertoli cells

197   (vimentin). SARS-CoV-2 anti-serum colocalized with vimentin staining at the base of the tubules,

198   indicating that Sertoli cells are being infected (Fig 4C). However, SARS-CoV-2 staining was

199   sometimes observed in cells negative for vimentin indicating that cellular targets exist in

200   addition to Sertoli cells (presumably germ cells because of their localization) (Fig 4C, arrow

201   heads).

202

203   Distribution of SARS-CoV-2 Delta variant signal after 1 week of infection

204   Because of the mild disease manifestations of SARS-CoV-2 WA1 seen in many rhesus macaque

205   studies, we utilized the Delta variant for the next set of animals, which had become the

206   dominant circulating variant at the time of this study[26]. For IN22, at 1-week post infection, we

207   performed 2 PET/CT scans at 3- and 21-hours post probe injection to gain insights into the

208   dynamics of the probe distribution over time. This is an important aspect of probe function

209   because as the probe distributes from circulation into the tissue it will encounter virally

210   infected cells which will affect its distribution pattern. The three PET/CT scans of IN22, the

211   whole body (Fig 5A-D and S7-video, S8-video), the organ scan (Fig 5E-H and S9-video) and the

212   tissue scan (Fig 5I) are shown in Fig 5.

213   The front and side views of the 3-hour scan (Fig 5A, B and S7-video) and 21-hour scan

214   (Fig 5C, D and S8-video) reveal a highly dynamic system of probe distribution demonstrating

215   that the timing of the PET/CT scan after probe injection is an important consideration. The 3-

216   hour scan clearly captures a robust probe signal in the vasculature and chambers of the heart,

11

217   consistent with a large fraction of the probe still circulating in the blood after IV injection. A

218   strong lung signal is apparent in the 3-hour scan in contrast to the previous animal. Some signal

219   was also observed in the MGT with a very strong signal observed in the prostate in the 3-hour

220   scan. In the 21-hour scan, the lung probe signal remained much greater than observed in LP14

221   and was further distributed throughout the tissue. The prostate signal remained but decreased

222   substantially in the 21-hour scan while signal in the MGT was further amplified. For the most

223   part, an increase in signal was seen at tissue sites of probe labeling in the 21-hour scan. In

224   contrast, the vasculature signal decreased substantially, consistent with the movement of the

225   probe from blood, into tissues. However, some discrete probe labeling of certain vascular sites

226   remained, possibly indicating infection of the vasculature.

227   To better evaluate the probe signal in the lungs after Delta infection, the 3D

228   reconstruction of the IN22 lungs was isolated from the PET datasets, and the lung signal was

229   projected over the CT reconstruction of the skeleton (Fig 6A-D, S10-video). Both the 3-hour and

230   21-hour signals are significant and localized. The lung rotation series (Fig 6E and F) reveal a

231   major signal associated with the caudodorsal portion of the right lung and less signal associated

232   with the left lung. Single z images of the PET and CT signal in sagittal and transverse sections is

233   shown in Figs 6G-J to better facilitate the analysis of the relationship of CT revealed lung

234   pathology with the PET signal. This comparison reveals an overlap of the opaque lung signal and

235   greater PET signal in the right lung in contrast to the more CT transparent left lung tissue (Fig

236   6G-J). The stronger PET signal in the right lung observed in the whole-body scan is recapitulated

237   in the organ scan (Fig 6K-O). This animal had overt gross pathology associated with the dorsal

238   aspects of the right lower lung lobe as highlighted in the magnified inset (Fig 6L).

12

239   Histopathology of this region revealed marked pulmonary interstitial inflammation and

240 type II pneumocyte hyperplasia (Fig 1D, and 6P-S). The projection of the PET signal over the

241 photo (6N) shows a strong PET signal in multiple lung lobes and located adjacent to the focally

242 extensive areas of consolidation (red and inflamed areas). A similar strong PET signal is

243 observed in several areas of the left lung, with a major PET signal associated with the caudal

244 aspect of the upper lobe of the left lung. An overlay of the unnormalized PET over a CT

245 projection that reveals lung structure and fluid in the lung (Fig 6O) further details the

246 relationship between the areas with evidence of pneumonia and the PET signal. The PET signals

247 tend to be adjacent to opaque regions potentially caused by fluids and the regions of

248 consolidation visible in the photo.

249   Next, we evaluated paraffin blocks of the right lower lobe by H&E (Fig 6P and R) and

250 immunofluorescent staining for SARS-CoV-2 (Fig 6Q and S). In regions of pneumonia (Fig 6P),

251 the interstitium and alveolar spaces are expanded by inflammatory infiltrate. In these same

252 regions, SARS-CoV-2 infected cells are scattered throughout (Fig 6Q). Higher magnification

253 imaging of the H&E stain (Fig 6R) reveals the inflammatory infiltrate is composed predominately

254 of macrophages with lesser neutrophils (arrowheads). Alveolar septa are frequently lined by

255 type II pneumocytes (arrows). SARS-CoV-2 staining (Fig 6S) reveals infected cells within alveoli

256 (arrows) and lining alveolar septa (arrowheads).

257   To validate the accuracy of our SARS-CoV-2 staining results, 2-color

258 immunofluorescence staining for spike and nucleocapsid was used to identify SARS-CoV-2

259 infected cells in the right lung (Fig 6T). Spectral imaging confirmed that the fluorescence signal

260 associated with the double positive cells is consistent with the specific fluorophores utilized for

13

261   antigen visualization. Additional fluorescent staining shows focal nature of infected cells in a

262   large piece of lung tissue (Fig 6U-W). The 2-color imaging is a powerful method to validate the

263   identification of SARS-CoV-2 infected cells. Spectral imaging of left lung tissue stained for NC

264   and dsRNA was used as an alternate approach to identify infected cells (Fig is shown in panels

265   6X-Z). The spectrum shown in Fig 6Z confirms that the cells identified in panel 6Y are

266   specifically double stained with the antibodies to dsRNA and SARS-CoVCoV-2 NC.

267   To evaluate the probe signal in the MGT after Delta infection, we compared the 3-hour

268   and 21-hour PET/CT signal in the IN22 MGT (Fig 7A-D); the isolated PET signal of the MGT of

269   both scans is shown below (Fig 7E-H). A signal is apparent in the base of the testes that

270   becomes more diffuse at the 21-hour timepoint. There is also a signal apparent just above both

271   testes in the 3-hour scan that increases at 21-hours and is most prominent above the right teste

272   (Fig 7A-H, indicated by white asterisk). Examination of both scans indicates that the probe

273   signal was initially associated with the vasculature, but it persisted and accumulated adjacent to

274   the top of testes in the 21-hour scan. This PET signal is associated with the vasculature of the

275   spermatic cord as is visible in the CT projections and the PET overlays in the 21-hour scan (Fig

276   7I-L) and after the necropsy (Fig 7M-P). The post necropsy signal matches the *in vivo* scan with

277   the left testicle having a persistent signal throughout the spermatic cord and a more localized

278   signal on the top of the right teste. To confirm infection in these tissues, the tissue block with

279   the greatest PET signal (L Test 1, Fig 5I) was sectioned for genomic and microscopic analysis.

280   Bulk RNA was isolated from 2 tissue sections and qPCR analysis of the SARS-CoV-2 N gene

281   revealed the presence of viral RNA (2.03 Copies N1/ul). Immunofluorescence analysis of the

282   PCR positive tissue derived from the same block revealed the presence of sparse cells double

14

283   positive for spike and nucleocapsid primarily found in the interstitial space (Fig 7Q and R).

284   Staining of penile tissue from an uninfected macaque (Fig 7S) reveals robust ACE2 expression in

285   the venous spaces of the corpus cavernosum. Multiple SARS-CoV-2 infected cells in the penis

286   were revealed by double staining for nucleocapsid and dsRNA (J2) (Fig 7T-W).

287

288   **Longitudinal analysis of SARS-CoV-2 Delta variant distribution 1- and 2-weeks post-infection**

289   For the final pilot study, we performed two longitudinal PET/CT scans, at 1- and 2-weeks post

290   challenge with the Delta variant, on a single animal (JF82). The goal of this study was to

291   determine if the ^{64}Cu-F(ab')2 probe could provide novel insights into the spatiotemporal

292   dynamics of SARS-CoV-2 infection with sequential PET/CT scans. A front and side view of the

293   sequential PET/CT scans at 1-week (Fig 8A-B) and 2-weeks (Fig 8C-D) reveals dynamic changes

294   in various organ systems. For example, there is a decrease in the signal of the lungs between

295   week one and two while MGT signal increases. These changes are illustrated in the front (Fig

296   8E) and side (Fig 8F) view overlay of the 1-week (shown in red) and 2-week (shown in blue)

297   timepoints. Areas with blue signal indicate increased signal in week 2 relative to week 1 and

298   areas with red signal indicate where the week 1 scan had greater signal. Areas with white signal

299   indicate where there is high PET signal in both scans. The post necropsy organ scan (Fig 8G-J,

300   S7-video) and the tissue scan (Fig 8K) similarly show probe signal associated with both the lungs

301   and MGT.

302   To better compare the probe signal in the lungs of JF82 at the 1-week (Fig 9A-B) and 2-

303   week (Fig 9C-D) timepoints, the 3D reconstruction of the JF82 lungs was isolated from the PET

304   datasets and projected over the CT reconstruction of the skeleton (Fig 9A-D). Both the 1- and

15

305   2-week lung signals are apparent and localized with a level of signal comparable to the previous

306   animal (IN22) infected with the Delta variant. An evaluation of the data set revealed a PET

307   signal overlying a region of opacity in the lower lobe of the left lung as designated with the

308   asterisks in several of the panels (Fig 9A-B, 9G-L). The lung rotation series shown for week 1

309   (Fig 9E) and week 2 (Fig 9F) reveal a major signal associated with the dorsal side of the left lung

310   at both timepoints and less signal associated with the right lung in the week 1 scan. Evaluation

311   of signal from coronal sections of the week 1 PET/CT overlay (Fig 9G) and CT alone (Fig 9I)

312   reveals an overlap of the probe signal with an opaque region consistent with focal pneumonia.

313   It is notable that both the PET and CT signal associated with this spot in the left lung are gone in

314   the week 2 scan (Fig 9H and J). This is consistent with reports that the lung pathology observed

315   in the rhesus macaque model is most apparent after 1 week of infection and can wane by week

316   2[25]. To better illustrate the change between week 1 and week 2, the week 1 scan in red and the

317   week 2 scan in blue were overlaid with the week 1 CT signal (Fig 9K and L). Microscopic analysis

318   revealed pulmonary infiltrates were still present in the alveolar space at necropsy (Fig 1E).

319   However, no infected cells were detected with immunofluorescence using an anti-SARS-CoV-2

320   antibody in FFPE tissue. These findings are suggestive of a resolving infection which is

321   supported by the histopathology (Fig 1E) and viral RNA levels (Fig 1F and G).

322   We next evaluated the signal associated with the MGT of JF82 as illustrated in Fig 10,

323   which presents the front and near side view (~45˚) of the abdominal area of the week 1 (Fig 10A

324   and D), week 2 (10B and E), and overlay (10C and F). The overlay (Fig 10C and F) reveals the

325   dynamics of the probe signal in the MGT of JF82 in the first 2 weeks of SARS-CoV-2 infection.

326   The white signal in the overlay reveals that the probe signal is maintained in the prostate, the

16

327   vasculature at the base of the spermatic cord, and the base of the testes. To gain additional

328   insights into the MGT associated signal at the 2 time points, we isolated the MGT volumes and

329   3D projected the signal (Fig 10G-J). In the week 1 scan (Fig 10G-H), a signal associated with the

330   root of the penis is also apparent in addition to the signal associated with the vasculature at the

331   base of the spermatic cord and the base of the testes. In the week 2 scan, the signal becomes

332   more diffuse, spreading throughout the penis and testes, and extending into the spermatic

333   cord, especially into the right spermatic cord. To better visualize the signals associated with the

334   different tissues, we isolated the volumes containing the penile signal for the week 2 scan (Fig

335   10K-M). The signal distribution throughout the penis at week 2 is readily apparent and distinct

336   from the signal associated with the spermatic cord. It is notable that the probe signal associated

337   with the MGT becomes better distributed and more pronounced in the week 2 scan, consistent

338   with a spreading infection in the MGT between week 1 and week 2. In contrast, a focus of

339   infection in the right lung (Fig 9) of the same animal is observed in the week 1 scan and

340   resolved in the week 2 scan.

341   Histopathology of testicular tissue from JF82 revealed multifocal regions of degenerate

342   seminiferous tubules characterized by a complete loss of germ cells and spermatids (Fig 10N).

343   These regions also have evidence of edema as revealed by increased spaces between individual

344   seminiferous tubules. Degenerate seminiferous tubules occasionally contained macrophages

345   with phagocytosed spermatids, and the adjacent interstitium was infiltrated by low numbers of

346   lymphocytes and plasma cells. To further characterize the degenerative changes noted on H&E,

347   immunofluorescence for CD206 - a mannose receptor present on monocytes, macrophages[27],

348   and mature spermatids[28-30] - and caspase 3 - a cellular marker of apoptosis - was performed.

17

349   Degenerate seminiferous tubules were readily identified by the marked decrease in CD206

350   expression (due to loss of mature spermatids) and increased expression of caspase 3 compared

351   to adjacent, nondegenerate, tubules (Fig 10O, Q-S). Evidence of intra-tubule macrophages was

352   readily apparent (Fig. 10R, S). SARS-CoV-2 infected cells can be identified in the JF82 testes with

353   triple staining for NSP8, nucleocapsid, and SARS-CoV-2 anti-sera (Fig 10T and U).

354

355   **Comparison of PET signal between animals**

356   A comparison of the PET/CT scans of 3 SARS-CoV-2 infected rhesus macaques is revealing in

357   terms of the dynamics of infection and the utility of this technique to study COVID-19. In Fig

358   11A-D we present a comparative rotation series of the PET signal withing the lung volumes of

359   all scans. Although there are differences in the lung signal of each scan, the Delta variant

360   utilized for infection of IN22 (Fig 11B) and JF82 (Fig 11C-D) is associated with increased

361   pathology[26] (Fig 1C-E, Fig 5, and Fig 8) and increased PET signal (Fig 11B-D) without a clear

362   difference in viral load in nasal swab or saliva at 1 week after challenge (Fig 1F and G) compared

363   to LP14. This is consistent to similar viral loads between WA1 and the Delta variant in a recent

364   report[26].

365   The probe signal associated with the MGT was not anticipated, but apparent in all 3

366   animals. This reveals that infection of MGT is consistently seen in the rhesus macaque model of

367   SARS-CoV2 IN/IT challenge. A comparison of the isolated MGT PET signal from the four whole-

368   body PET scans of 3 SARS-CoV-2 infected rhesus macaques (Fig 11E-H) presented as a rotation

369   series further reveals the dynamics of SARS-CoV-2 after infection. The difference in MGT signal

370   between the animal infected with WA1 (LP14) and the animals infected with the Delta variant

371   (IN22 and JF82) at week 1 is much less pronounced than that seen in the lungs. In all week 1

372   MGT scans, the signal is asymmetrically distributed with diffuse signal throughout the testicles,

373   an increased signal at the base and top of the testes, and a signal associated with the root of

374   the penis (Fig 11E-G). The MGT PET signal is visibly increased in the week 2 scan relative to the

375   week one scan (Fig 11G, H) for JF82 indicating further spread of infection into the MGT at that

376   time. Another obvious difference between the week 1 whole-body PET scans is a variable signal

377   associated with the heart and liver as shown in Fig 11I-K. LP14 had a diffuse PET signal

378   throughout the liver (Fig 11I). In contrast, the IN22 PET signal (Fig 11J) was primarily localized

379   with the right side of the liver and in JF82 the PET signal (Fig 11K) was localized to the base of

380   the liver. Additionally, the extent of labeling of the heart is variable with JF82 and IN22 having a

381   greater signal than LP14 (Fig 11L).

382   To take advantage of the quantitative aspects of PET detection, we isolated the total

383   standard uptake value (SUV) of the PET signal associated with the CT defined volumes as

384   plotted in Fig 11L. The 3 animals scanned 1 week (W1) post SARS-CoV-2 challenge are

385   presented together for the whole-body (WB) scan signal and all evaluated tissues. The single

386   week 2 (W2) PET signal of JF82 is presented for comparison. The WB values for all scans are

387   clustered revealing the reproducible nature of evaluation of the PET signal. An increase in the

388   total SUV between week 1 and week 2 for the MGT and testes volumes is consistent with the

389   increase of signal suggested by visual inspection of the isolated tissues (Fig 10, Fig 11G and H).

390   Another relevant tissue with PET signal observed in all 3 animals is the prostate. Probe

391   labeling of the prostate first became apparent in the early PET scan (3 hr. after injection) of

392   IN22 where it was among the strongest, non-kidney associated signals (Fig 5A and B).

19

393   Therefore, we revaluated the PET/CT data sets for the 3 animals. We were able to detect a

394   signal associated with the prostate in all animals (marked by white asterisks, Fig 12A-F). An

395   inset showing a sagittal slice of the PET/CT shows the localization of the prostate within the

396   small white circle for each animal. PET signal was also isolated within the penile volume of the

397   whole-body scan for IN22 1-week post infection (Fig 12G-I) and 2-weeks post infection for JF82

398   (Fig 12J-L). LP14 is excluded from this analysis because the penile tissue was not collected. The

399   same general distribution of PET signal is seen in the organ scan of IN22 (Fig 12M) and JF82 (Fig

400   12N). The localization of the PET signal is further defined in the tissue scan of the cryomolds

401   shown with (Fig 12O and Q) and without (Fig 12P and R) PET signal for each animal. There is

402   PET signal associated with the penile tissue with a stronger signal associated with the penile

403   root of IN22 and the glans of JF82. This PET/CT guided necropsy of the MGT reveals a

404   persistent signal associated with the penile tissue of these 2 animals. All 3 animals had an

405   apparent PET signal associated with the testes at the 1-week timepoint and that signal

406   increased in the testes in the week 2 scan (Fig 12Q-T, quantified in Fig 11O). The

407   histopathologic analyses of the testes from all three animals are shown in Fig 12S-U. Testicular

408   degeneration was noted in seminiferous tubules of JF82 (Fig. 10N). Panels demonstrate normal

409   spermatogenesis or lack thereof in JF82 (Fig. 12N, O, R, S).

410   In addition, all animals had a PET signal located at the top of each testicle, where the

411   spermatic cord connects with testicle. A dissection of the rhesus macaque testicular anatomy is

412   shown in Fig 13A-C. The spermatic cord contains the vasculature supplying blood to the

413   testicles, the vas deferens which transports mature sperm produced in the testes, and the

414   cremaster muscle (Fig 13A). The position in natural context of the macaque penis, testes, and

415   spermatic cord are shown in Fig 13B. A magnified view of the vasculature of the pampiniform

416   plexus is shown in Fig 13C. As shown in the IN22 MGT PET/CT series (Fig 13D-G), there is a

417   major signal associated with the top of the testicles, especially the right testicle. A further

418   examination of this signal within the PET/CT data set demonstrates it is located just above the

419   testicle in the yellow volume (Fig 13D-G). This yellow volume is overlapping with a vasculature

420   structure consistent with the pampiniform plexus visualized by CT (Fig 10G and B). The signal

421   associated with the pampiniform plexus and spermatic cord is seen in the 1-week scan of all

422   animals in front (Fig 13H, J, and L) and rotate 45˚ view (Fig 13I, K, and M) outside of the ovals

423   indicating the tetes. The signal associated with the pampiniform plexus and spermatic cord for

424   LP14 can be seen outside of the white ovals (Fig 13L-Q).

425

426   **Principal component analysis of PET SUV signals**

427   The PET signal includes several parameters in each anatomical area, each of which provide

428   different insights into the distribution of the probe within the tissue. For example, the total SUV

429   (Fig 11L), provides insights into the overall signal in each tissue/animal. However, the total SUV

430   does not account for variability in tissue size and shape. The mean SUV provides insights into

431   the relative intensity of PET signal in each tissue (Fig 14A). This comparison of mean SUV reveals

432   the relative intensity of the signal across tissues, with the prostate having consistently high

433   signal in all animals. In contrast, the total SUV/whole body Total SUV for the different tissues

434   illustrates the percentages of the total whole-body signal in each tissue without consideration

435   of the size of each tissue relative to the other (Fig 14B). All 7 PET parameters for each tissue are

436   shown in the heatmap (Fig 14C), which reveals that different tissues have unique signal

21

437   characteristics. From this analysis, it is evident that the prostate signal of IN22 and JF82 have

438   the highest mean SUV and standard deviation with relatively a high median SUV being also seen

439   in the prostate of the 3rd animal LP14. For example, the prostate signal of IN22 and JF82 has the

440   highest mean SUV and standard deviation with relatively a high median SUV being also seen in

441   the prostate of the 3rd animal LP14, indicating a more clustered signal compared to the tissues

442   with the highest total SUV.

443   To facilitate the use of our PET data to gain insights into our data set we utilized

444   Principal Component Analysis (PCA) followed by hierarchical clustering to examine the data

445   from all scans of the 3 animals. To cluster tissues according to their SUV signal characteristics,

446   we applied PCA including all variables obtained from the SUV measurements (i.e., Total SUV,

447   Total SUV Whole Body ratio, Mean SUV, Median SUV, Standard Deviation SUV, Max SUV, and

448   Kurtosis) for each tissue and animal. After this analysis, we observed 4 different clusters that

449   correspond to tissues that display very distinct SUV signals. The clustering captures the prostate

450   signal described in the heat map where they are part of cluster 4 (dark blue group). Of note, the

451   major right lung signal of IN22 also clusters within this group, while the prostate signal of LP14

452   does not (Fig 14D). The evident PET signal observed in the lungs of the Delta variant animals

453   IN22 and JF82 are part of the cluster 3 (green group) (Fig 14D) revealing their similarity with its

454   small foci of high signal and increased kurtosis value (indicating data heavy tails or more

455   outliers) consistent with the signal variability. The higher kurtosis is also associated with penile

456   and testes signal of all the animals in the red and light blue clusters 1 and 2. This analysis allows

457   us to begin to appreciate the nature of the PET signal associated with the different tissues,

458   different animals, different viruses, and identify outliers.

22

459

460 **Discussion:**

461 The goal here was to develop a F(ab')2 based immunoPET probe to allow the visualization of

462 SARS-CoV-2 spike protein expression in the rhesus macaque infection model. This model is

463 clinically relevant as it was used to develop the highly successful vaccines now available against

464 SARS-CoV-2[31, 32]. The ability to detect anatomical sites of SARS-CoV-2 infection will facilitate

465 our understanding of COVID-19 disease severity and the mechanism of comorbidities in the

466 development of pathology. It could be especially useful in understanding long-COVID and its

467 underlying causes[33, 34]. This pilot study is a key step in the clinical development of this PET

468 probe to visualize SARS-CoV-2 replication and to facilitate treatments for COVID-19. The

469 distribution of the probe is complex, but it can reveal sites of SARS-CoV-2 infection in the rhesus

470 macaque model.

471 The utility of the probe is best demonstrated by the temporal association of the PET

472 probe with CT detected lung pathology between weeks 1 and 2 in JF82. A PET signal was clearly

473 associated with an opaque region (pneumonia) in the left lung in the week 1 scan, but both the

474 PET signal and CT detected pneumonia are not present in the week 2 scan, validating this

475 technique. The overlays, shown in Fig 9, further illustrate this transient lung pathology

476 detected by comparing the two PET/CT scans separated by one week. Supporting this

477 interpretation of the PET/CT data, the pathology report shows that the left lung of JF82 has

478 type II pneumocyte hyperplasia and inflammatory infiltrate consistent with the normal course

479 of infection observed in the rhesus macaque model. Overall, the lung pathology associated

480 with SARS-CoV-2 in our three animals was consistent with the observation of many infected

23

481   rhesus macaques where the lung pathology was typically mild and peaked at 1 week after IN/IT

482   challenge. This dynamic was generally observed for lung associated signal in this limited pilot

483   study. There was some consolidation and inflammation observed in animal IN22 and this

484   coincided with an adjacent PET signal in both animals infected with the Delta variant.

485   Further validation of the PET/CT probe's ability to identify areas of infection at sites

486   other than the lungs and its utility in understanding COVID-19 pathogenesis was the revelation

487   of a reproducible infection of the MGT. In all three animals, the probe was associated with the

488   prostate, penis, pampiniform plexus, and testicles. We have been able to identify SARS-CoV-2

489   infected cells in the testicles of all 3 animals. Comparing the longitudinal PET scans of JF82

490   reveals that while the lung pathology and signal wane between week 1 and 2, the signal of the

491   MGT, and more specifically in the testicles increases in week 2. Consistent with increased

492   testicular infection at week 2 indicated in the PET scan, H&E staining of the JF82 testes revealed

493   a unique pathology consisting of denuded stretches of the twisted and intertwined

494   seminiferous tubules (presenting as a tube cluster). Spermatids were absent in these

495   degenerate regions and the remaining Sertoli cells were undergoing apoptosis, seen through

496   caspase 3 staining (Fig. 10S). Local inflammation, or orchitis, was suggested by immune

497   infiltrates (Fig. 10R). Both the PET signal and pathology is greater in the left testicle of JF82.

498   Staining macrophages and mature spermatids for CD206 and all cells for caspase 3 activation

499   reveals a severe, acute response within short stretches of the seminiferous tubules where the

500   Sertoli cells are undergoing apoptosis due to inflammasome activation (caspase 3 activation),

501   and no spermatids are present consistent with an ongoing acute infection (Fig. 10N-S). We

502   have detected infected cells within the JF82 testes ((Fig. 10T, U) and the relationship between

24

503   the infected cells and testicular pathology is ongoing. Similar decreases in the cellular content

504   of the seminiferous tubules and sloughing of Sertoli cells and spermatids into the lumen have

505   been reported in multiple studies of autopsy tissues from COVID-19 related fatalities[35-40].

506   Our results suggest that SARS-CoV-2 rapidly and efficiently infects multiple tissues of the

507   male genital tract (MGT) early during infection in rhesus macaques. The complex vasculature

508   and known ACE2 expression of the tissues of the MGT make it a potential target of the virus[11,

509   41-43]. The SARS-CoV-2 infection of the testicles has been reported in mouse and hamster

510   respiratory challenge models[44-46]. Likewise, the testicles are also a target of Ebola and Zika virus

511   during systemic infection[47]. We observed a similar distribution of PET-probe signal in all 3

512   animals in the week 1 scan with labeling of the prostate, root of the penis, the top the testicles

513   and a second region of labeling at the base of the testicles (Fig. 11E-H). The signal above the

514   testicles localizes to the pampiniform plexus and vasculature of the spermatic cord while the

515   signal at the base of the testes is less clear, but appears to be associated with the cauda

516   epididymis, the highly vascularized tail of the epididymis that serves as the storage site for

517   mature sperm. A further dissection of the testicles before the organ scan should facilitate a

518   detailed localization of the PET signal associated with the MGT in future studies.

519   Although these studies were done with a rhesus macaque model, it is reasonable to

520   suggest that these observations may also apply to humans infected with SARS-CoV-2 because of

521   several clinical observations relating to male sexual health and fertility. It is highly relevant in

522   this extrapolation to consider that we have identified 4 distinct tissues where SARS-CoV-2

523   infection could impact male sexual health and fertility: SARS-CoV-2 infection of the prostate,

524   penis, pampiniform plexus, and testicles. The infection of the MGT and associated pathology

525   has been suggested by several publications and clinical studies. The prostate is known to be

526   ACE2 positive.[48] Interest in SARS-CoV-2 infection of the prostate has focused on two areas. First

527   is the potential impact on treatment of benign prostate hyperplasia[49] and prostate cancer [50]

528   with androgen deprivation therapy on the severity of COVID-19[51] and secondly, the potential

529   impact of SARS-CoV-2 infection on prostate cancer treatments. It is notable that prostate

530   cancers are known to express high levels of transmembrane serine protease 2, TMPRSS2[52],

531   which is known to activate the SARS-CoV-2 spike protein to its optimal fusogenic potential[53].

532   Multiple studies have explored this space and it does not appear that SARS-CoV-2 infection is

533   associated with an increase in prostate cancer[54]. In contrast, another study suggests that

534   infection with SARS-CoV-2 may be associated with an increase in prostate specific antigen (PSA)

535   detection in plasma[55]. Future studies are needed to confirm whether the robust signal of the

536   SARS-CoV-2 PET/CT probe reflects a high-level infection of the human prostate and its

537   subsequent impact on male sexual health and fertility[56, 57]. SARS-CoV-2 infection of the penis is

538   potentially associated with the vasculature of the corpus cavernosum, which expresses high

539   levels of ACE2 in the rhesus macaque and human penile tissue (Fig 7S) [43, 58]. Because the corpus

540   cavernosum plays a key role in erectile function, the inflammation caused by SARS-CoV-2

541   infection of the penile vasculature is hypothesized to lead to erectile dysfunction (ED). This has

542   indeed been reported to be linked to COVID-19[43, 59, 60]. In addition, treatments for ED such as

543   Viagra and Cialis are known to affect the renin-angiotensin-aldosterone-system where ACE2

544   functions as a part of the physiologic regulation of blood flow associated with normal erectile

545   function[61].

546   A potential impact of COVID-19 infection on the pampiniform plexus might be suggested

547   by several case reports of COVID-19 associated thrombosis located in the pampiniform plexus[62-

548   65]. Additionally, the signal distribution of the left and right testes is distinct, with the signal of

549   the right testicle being more focused at the top of the testicle while the signal on the left

550   testicle being more distributed in the spermatic cord. This is reminiscent of the condition

551   known as varicocele, which manifests as varicose veins of the scrotum, and is prominent in the

552   left testicle relative to the right testicle[66]. This is due to the left testicle receiving its blood flow

553   from the left renal vein which exposes it to higher blood pressure and slower blood flow[67]. This

554   difference could be insightful if it is confirmed in more animals.

555   The potential infection of the testicles by SARS-CoV-2 could be highly impactful on male

556   fertility, potentially decreasing sperm count and semen quality[47, 68-70]. It is known that SARS-

557   CoV-2 infection in humans is associated with oligo- and azoospermia and a transient decrease

558   in fertility after infection[36, 38, 66, 68, 71, 72]. One study found that fertility amongst infected men

559   was reduced and returned to baseline 3-6 months after SARS-CoV-2 infection[73]. This decrease in

560   fertility was not seen in infected women or men who received a SARS-CoV-2 vaccination. We

561   find that the pathology associated with the testicles in the week 2 necropsy is extreme, with

562   apparent ablation of sperm production within short regions of the seminiferous tubules and

563   with accompanying immune infiltration consistent with an emerging COVID-19 associated

564   orchitis[64, 74]. Multiple studies have reported a decrease in testosterone after SARS-CoV-2

565   infection[56, 75, 76]. Leydig cells, which produce testosterone, are known targets of SARS-CoV-2[35,

566   37, 77]. The decrease in testosterone correlates with disease severity[76, 78]. This susceptibility of

567   the MGT to infection with SARS-CoV-2 may be consideration in the of higher mortality

568   associated with COVID-19 in men compared to women. The direct infection of the testicles

569   observed in the NHP studies presented here are consistent with the MGT pathology reported in

570   men[35-40]. The infection of the MGT may be a common outcome in SARS-CoV-2 infection. We

571   suggest further study in mild, and even in asymptomatic infection, in men and macaques is

572   clearly required. Because of the four distinct mechanisms negatively impacting human male

573   sexual health and fertility, and the observation of all four mechanisms in all animals evaluated

574   to date, we feel compelled to report this information at this early stage of study and evaluation.

575   Using a novel ^{64}Cu-labelled F(ab')2 probe targeting the SARS-CoV-2 spike protein, we

576   have found that it is possible to identify sites of SARS-CoV-2 infection in the rhesus macaque

577   infection model using a PET/CT scan. The rapid and consistent spread of SARS-CoV-2 infection

578   to the MGT in the first week of infection in the rhesus macaque suggests this could be an

579   important post pandemic health consideration as those infected during the pandemic develop

580   advanced disease and other manifestations of long COVID-19. Currently, there is no other

581   methods that allows for the unbiased discovery of novel anatomical sites of SARS-CoV-2

582   infection. We believe the immunoPET technique described here will be an important addition

583   to the toolkit for studying and understanding SARS-CoV-2 pathogenesis. The availability of an

584   immunoPET probe to SARS-CoV-2 in the clinical setting has the potential to reveal the

585   underlying role of disseminated viral infection in long COVID and could guide therapeutic

586   interventions to resolve SARS-CoV-2 related sequalae which could be a major health concern

587   for the lifetimes of those infected during the COVID-19 pandemic.

588

595

596

597   **Material and Methods**

598   **Preparation of F(ab)2**

599   CR3022-IgG1 was acquired from Absolute Antibody (#Ab01680-10.0, Absolute Antibody). The

600   IgG1 was digested into F(ab)2 as previously described. Briefly, a Genovis FragIT antibody

601   digestion kit (#A2-FR2-100, Genovis) was used according to manufacturer's protocol. CR3022

602   was digested by adding to the FragIT column and rocking for 1 hr. at room temperature. The

603   column was then centrifuged to elute fragments. Fc fragments were removed after incubation

604   with the CaptureSelect Fc Column. F(ab')2 fragments were eluted from this column and size

605   was confirmed using SDS-PAGE.

606

607   **DOTA Labeling of Antibody**

608   CR3022-F(ab)2 was labeled with the chelator dodecane tetra-acetic acid (DOTA) for the

609   attachment of ^{64}Cu. Chelex 100 chelating resin (#142-1253, BioRad) was used to prepare two

610   buffers: 0.1M sodium phosphate (pH 7.3) and 0.1M ammonium acetate (pH 5.5). Five grams of

29

611 Chelex was added to 100ml of each buffer and stirred at room temperature for 1 hour. Buffers

612 were then filter sterilized using 0.22 μM filters. CR3022-F(ab')2 was buffer exchanged into the

613 prepared 0.1 M sodium phosphate using Zeba columns (ThermoFisher, USA). DOTA-NHS-ester

614 (#B-280, Macrocyclics) was dissolved in dimethyl sulfoxide (DMSO) at a concentration of 10mM.

615 A 1:10 dilution of 1M sodium bicarbonate was made into a tube containing F(ab')2 in sodium

616 phosphate and 10mM DOTA was added at a molar ratio of 5:1. The tube was mixed and left to

617 rock at 37C for 1.5 hours. The labeled F(ab')2 was then buffer exchanged into fresh 0.1 M

618 sodium phosphate using a Zeba column.

619

620 **^{64}Cu labeling**

621 Before labeling DOTA conjugated F(ab')2 was buffer exchanged into freshly prepared 0.1M

622 ammonium acetate (pH 5.5) prepared with Chelex 100 using 10kDa cutoff Amicon centrifugal

623 microfilters (Cork, IRL). Cu^{64} chloride was obtained from Washington University, St. Louis MO

624 and shipped overnight to TNPRC. All work with Cu^{64} was performed inside a lead castle. The

625 radioactivity of the Cu^{64} was measured using an Atom Force 500 dose calibrator and recorded.

626 Next the Cu^{64} was added to a tube containing the DOTA labeled F(ab')2 in 0.1 M ammonium

627 acetate and incubated at 37°C for 1 hour while rotating. The labeled F(ab')2 probe was then

628 separated from unlabeled Cu^{64} and buffer exchanged into PBS via sequential centrifugation

629 steps using 10kDa cutoff Amicon centrifugal microfilters to a final volume of ~20μl. The

630 conjugated probe was then diluted to the final volume in PBS in sterile glass vials and drawn

631 into single dose syringes. Each dose typically labelled in the 1-3 mCi per dose.

632

Animals and virus

The virus used for experimental infection of LP14 was SARS-CoV-2; 2019-nCoV/USA-WA1/2020

(https://www.ncbi.nlm.nih.gov/nuccore; accession number MN985325.1) obtained from BEI

resources (BEI #NR-52281). Virus stock was prepared in Vero E6 cells and sequence confirmed

by deep sequencing. Plaque assays were performed in Vero E6 cells. Vero E6 cells were

acquired from ATCC (Manassas, VA). The virus used for experimental infection of IN22 and JF82

was SARS-CoV-2; hCoV-19/USA/MD-HP05647/2021 (Lineage B.1.617.2; Delta variant) obtained

from BEI resources (BEI #NR-55672). Delta variant stock was expanded using Calu-3 cells and

prepared as above using Vero E6 cells.

Three male rhesus macaques (Macaca mulatta) were used in this study. All animals were

housed at the Tulane National Primate Research Center (TNPRC, Covington, LA) which is

accredited by the Association for the Assessment and Accreditation of Laboratory Animal Care.

All procedures were reviewed and approved by the Tulane University Institutional Animal Use

Committee under protocol number P0452.One animal was inoculated with 1.1×10^6 tissue

culture infectious dose ($TCID_{50}$) of the WA1 strain of SARS-CoV-2 via concomitant

intratracheal/intranasal instillation (1mL intratracheal, 500µL per each nare). This animal was

necropsied 8 days post-infection. The remaining two animals were inoculated with 1.12×10^6

$TCID_{50}$ of the delta variant of SARS-CoV-2 via the same route. One animal was necropsied at day

7 and one at day 14 post-infection. All animals were intravenously infused with 0.5 mg/kg of

the radiolabeled F(ab')2 probe and JF82 was infused on two separate occasions. Macaque LP14

received 4 mCi, JF82 and IN22 received 1.3 and 1,4 mCi respectively on Dec 9, and JF82 received

an additional dose of 0.7 mCi on Dec 15. LP14 had nasal and salivary swabs taken at day 7. IN22

655 had swabs taken at days 3, 5, and 7 post-infection, while JF82 had swabs taken at days 3, 5, 7,

656 and 14.

657

658 **PET/CT Imaging and Necropsy**

659 PET/CT guided necropsies were performed in three sequential phases each separated by a

660 PET/CT followed by a period of analysis and sampling (1. whole-body, 2. organ, and 3. tissue).

661 First, whole-body scans were acquired prior to sending the animal to necropsy. Following

662 euthanasia, all major organ systems were removed (pluck, gastrointestinal tract, liver, spleen,

663 kidneys, urinary bladder, testicles, penis, prostate, seminal vesicles, nasal turbinate, lymph

664 nodes, carotid artery, cervical spinal cord, and brain) placed in a clear, plastic, sealable

665 container and sent back to PET/CT for an "organ scan". After the organ scans were

666 reconstructed, "hot" regions of each major organ (as seen on the organ scan) were sampled

667 and placed in cryomolds. The final "tissue" scan was acquired by placing the cryomolds in a

668 clear, plastic, sealable container and scanning them with the PET/CT. Following acquisition of

669 the tissue scan, cryomolds were filled with OCT and frozen on dry ice. All remaining tissue (not

670 placed in cryomolds) was placed in zinc-formalin fixative. All samples were stored for 5 days

671 before being removed from containment.

672

673 **PET/CT Image Analysis**

674 Acquired PET/CT whole-body images were analyzed using the MIM Software (MIM Software

675 Inc., Cleveland, OH). The PET and CT scans were reconstructed using the software and PETCT

676 fusions were created to analyze regions of interest through axial, sagittal, and coronal views.

677   The PET scans were presented in calculated Standardized Uptake Values, and all images were

678   set to the same scale (0-20 SUVbw). The PET scale was selected based on the overall signal

679   intensity of the PET scans, and the CT scale for optimal visibility of the tissues. Regions of

680   interest (ROI) were isolated using a combination of the Region Grow function and manual

681   contouring on a representative scan, then these regions were copied on subsequent scans of

682   the same animal using a specialized developed workflow. This workflow allows the software to

683   use the CT scans to map the selected ROI and locate that exact volume in subsequent scans.

684   Manual adjustments were then used to counter any changes in the animals' orientation

685   between scans. The areas within these regions were then extracted from the full scans, and the

686   anatomical regions were analyzed in both 2D cross-sections and 3D projections. 3D views are

687   maximum intensity projections of isolated ROI in the PET scans.

688   To cluster tissues according to their SUV signal characteristics, we used Principal Component

689   Analysis (PCA) where we included all variables obtained from the SUV measurements (i.e., Total

690   SUV, Total SUV Whole Body ratio, Mean SUV, Median SUV, Standard Deviation SUV, Max SUV,

691   and Kurtosis) for each tissue and animal. The clustering of each tissue was subsequently

692   obtained by agglomerative hierarchical clustering on the PCA results. After building an initial

693   hierarchical tree, the sum of within-cluster inertia was calculated for each partition. The

694   selected partition was the one with the higher relative loss of inertia. Both PCA and

695   agglomerative hierarchical clustering were performed using FactoMineR package and

696   Factoextra was used for visualization of the clustering results.

697

698   **Isolation and Quantification of viral RNA**

699 Viral load was quantified from pharyngeal and nasal swabs taken from infected animals at

700 TNPRC as previously described (1) Swab and bronchial brush samples were collected in 200 µL

701 of DNA/RNA Shield 1× (catalog number R1200; Zymo Research, Irvine, CA) and extracted for

702 viral RNA using the Quick-RNA viral kit (catalog number R1034/5; Zymo Research). The Viral

703 RNA Buffer was dispensed directly to the swab in the DNA/RNA Shield. A modification to the

704 manufacturers' protocol was made to insert the swab directly into the spin column to

705 centrifugate, allowing all the solution to cross the spin column membrane. The viral RNA was

706 then eluted (45 µL) from which 5 µL was added in a 0.1-mL fast 96-well optical microtiter plate

707 format (catalog number 4346906; Thermo Fisher Scientific, Waltham, MA) for a 20-µL real-time

708 quantitative RT-PCR (RT-qPCR) reaction. The RT-qPCR reaction used TaqPath 1-Step Multiplex

709 Master Mix (catalog number A28527; Thermo Fisher Scientific) along with the 2019-nCoV RUO

710 Kit (catalog number 10006713; IDTDNA, Coralville, IA), a premix of forward and reverse primers

711 and a FAM-labeled probe targeting the N1 amplicon of the N gene of SARS2-nCoV19

712 (https://www.ncbi.nlm.nih.gov/nuccore; accession number MN908947). The reaction master

713 mix was added using an X-stream repeating pipette (Eppendorf, Hauppauge, NY) to the

714 microtiter plates, which were covered with optical film (catalog number 4311971; Thermo

715 Fisher Scientific), vortexed, and pulse centrifuged. The RT-qPCR reaction was subjected to RT-

716 qPCR at a program of uracil-DNA glycosylase incubation at 25°C for 2 minutes, room

717 temperature incubation at 50°C for 15 minutes, and an enzyme activation at 95°C for 2 minutes

718 followed by 40 cycles of a denaturing step at 95°C for 3 seconds and annealing at 60°C for 30

719 seconds. Fluorescence signals were detected with a QuantStudio 6 Sequence Detector (Applied

720 Biosystems, Foster City, CA). Data were captured and analyzed with Sequence Detector

721   Software version 1.3 (Applied Biosystems). Viral copy numbers were calculated by plotting Cq

722   values obtained from unknown (i.e., test) samples against a standard curve that represented

723   known viral copy numbers. The limit of detection of the viral RNA assay was 10 copies per

724   reaction volume. A 2019-nCoV–positive control (catalog number 10006625; IDTDNA) was

725   analyzed in parallel with every set of test samples to verify that the RT-qPCR master mix and

726   reagents were prepared correctly to produce amplification of the target nucleic acid. A non-

727   template control was included in the qPCR to ensure that there was no cross-contamination

728   between reactions.

729   OCT embedded tissue blocks were sectioned between 10-15 µM and 2-4 sections were

730   placed into RNAse free tubes. RNA extraction was carried out using a RNeasy Plus Mini Kit

731   (#74124, Qiagen), according to manufacturer's protocol. Briefly, 350ul of lysis buffer with

732   dithiothreitol (DTT) was added to the tubes containing sections. The tubes were vortexed

733   briefly then frozen at -20C. Once thawed the samples were again vigorously vortexed then

734   centrifuged for 3 minutes. Supernatant was removed and applied to the gDNA Eliminator spin

735   column. The flow-through was mixed with 350ul of 70% ethanol and added to a RNeasy spin

736   column. The spin column was washed three times with buffers RW1 and RPE. RNA was then

737   eluted using 30-50ul of RNAse free water. All steps prior to addition of lysis buffer were carried

738   out in a BSL3 facility.

739

740   **Tissue Processing and H&E Staining**

741   Tissue samples were collected in Zinc formalin (Anatech) and fixed for a minimum of 72 hours

742   before being washed and dehydrated using a Thermo Excelsior AS processor. Upon removal

743   from the processor, tissues were transferred to a Thermo Shandon Histocentre 3 embedding

744   station where they were submersed in warm paraffin and allowed to cool into blocks. From

745   these blocks, 5um sections were cut and mounted on charged glass slides, baked overnight at

746   60°C, and passed through Xylene, graded ethanol, and double distilled water to remove paraffin

747   and rehydrate tissue sections. A Leica Autostainer XL was used to complete the

748   deparaffinization, rehydration and routine hematoxylin and eosin stain. Slides were digitally

749   imaged with a NanoZoomer S360 (Hamamatsu) and subsequently examined by a board-

750   certified, veterinary pathologist using HALO software (Indica Labs).

751

752   **Fluorescent Immunohistochemistry of FFPE tissues**

753   5um sections of Formalin-fixed, paraffin-embedded (FFPE) tissues were mounted on charged

754   glass slides, baked for two hours at 60°C, and passed through Xylene, graded ethanol, and

755   double distilled water to remove paraffin and rehydrate tissue sections. A microwave was used

756   for heat induced epitope retrieval. Slides were heated in a high pH solution (Vector Labs H-

757   3301), rinsed in hot water, and transferred to a heated low pH solution (Vector Labs H-3300)

758   where they were allowed to cool to room temperature. Sections were washed in a solution of

759   phosphate-buffered saline and fish gelatin (PBS-FSG) and transferred to a humidified chamber,

760   for staining at room temperature. Lung sections were blocked with 10% normal goat serum

761   (NGS) for 40 minutes, followed by a 60-minute incubation with the anti-SARS primary antibody

762   diluted in NGS. Slides were washed and transferred back to the humidified chamber for a 40-

763   minute incubation with the secondary antibody, also diluted in NGS. Sequential staining of FFPE

764   testes, for CD206 and Caspase 3, was done as described above with 1% normal donkey serum

765   (NDS) being used in place of NGS for blocking and antibody dilutions. DAPI was used to label the

766   nuclei of each section. Slides were mounted using a homemade anti-quenching mounting

767   media containing Mowiol (Calbiochem #475904) and DABCO (Sigma #D2522) and imaged at

768   20X with a Zeiss Axio Slide Scanner.

769

PRIMARY ANTIBODY	SPECIES	COMPANY	CATALOG	DILUTION	SECONDARY ANTIBODY
SARS	Guinea Pig	BEI	NR-10361	1:1000	Goat anti-guinea pig Alexa Fluor488
CD206	Goat	R&D Systems	AF2532	1:50	Donkey anti-goat Alexa Fluor488
Caspase 3	Rabbit	Abcam	Ab13847	1:200	Donkey anti-rabbit Alexa Fluor555
DAPI		Invitrogen	D1306	1:20,000	

770

771   **Fluorescence Microscopy of OCT embedded tissues**

772   OCT embedded tissue were cryosectioned in a BSL3 facility between 10 and 15 μM. One or two

773   sections of each tissue were placed on glass microscope slides. Tissues were placed into an

774   airtight container containing 4% PFA in PIPES buffer. The container was sealed and thoroughly

775   decontaminated before being removed from the BSL3 facility. The remainder of the staining

776   took place outside of the BSL3. Tissue sections were treated with L-lysine (0.1%, SigmaAldrich)

777   to reduce background and non-specific interactions before being blocked using 3% BSA

778   (Invitrogen, ThermoFisher) for 30 minutes at room temperature. Staining with primary

779   antibodies was carried out at 37°C and secondary antibodies at room temperature. each for

780   1hr. Table of primary and secondary antibodies used is below. All slides were stained with

781   Hoechst (1:25,000, ThermoFisher, USA) for 15 minutes and washed with PBS between all steps.

782   Dako fluorescent mounting medium (#S302380-2, Agilent, USA) was used to mount cover slips

783   which were sealed with nail polish. A DeltaVision Ultra inverted microscope (Cytivia, USA) was

784   used to obtain images using the 10x, 20x, 60x, and 100x lenses. Images were deconvolved,

785   stitched, and projected using the softWoRx software (Applied Precision, USA).

Clone	Antibody	Target	Company	Catalog#	Dilution
	Rb pAb	Spike	Abcam	Ab272504	1:200
3A2	Ms mAb	Spike	Abcam	Ab272420	1:200
6H3	Ms mAb	NC	GeneTex	GTX632269	1:200
5A10	Ms mAb	NSP8	GeneTex	GTX632696	1:200
	Rb pAb	NC	Novus Biologicals	NB100-56576	1:200
	Rb pAb	NC	GeneTex	GTX135357	1:200
rJ2	Ms mAb j2	Anti-double stranded RNA	Millipore Sigma	MABE1134	1:1000

786

787

788

789   **Figure 1**. Study design and viral analysis of infected macaques. (A) Workflow of PET/CT guided

790   necropsy. (B) Schematic showing the study design of probe administration, PET/CT scans, and

791   infection. (C-E) Lung lesions were consistent with prior findings in NHPs infected with SARS-

792   CoV-2 and varied from minimal in LP14 (C), moderate in IN22 (D), and mild in JF82 (E). Insets

793   demonstrate the inflammatory infiltrate and in IN22 and JF82, type II pneumocyte hyperplasia

794   (arrows). (F and G) Viral load measurements for all three animals. (F) shows copies/swab of

795   genomic N while (G) shows copies/swab of subgenomic N.

796

38

797 **Figure 2.** LP14 PET/CT guided necropsy. (A and B) Whole-body PET/CT scans of LP14 8 days

798 post-infection. Front view (A) and rotated 45° (B) both shown. PET signal is display as SUV. (C)

799 Post necropsy PET/CT organ scan of LP14. (D and E) Images of tissues scanned in (C). (F) Overlay

800 of PET signal onto photograph of small pieces of tissue in cassettes. (G and H) Lung PET signal

801 was isolated and overlaid on whole body CT scans. Side (G) and front (H) view. (I and J) Isolated

802 lung PET volumes used in G and H are shown independently, side view (I) and front view (J). (K

803 and L) Single axial z-slice images of respiratory tract PET/CT signals are shown, each image

804 represents a single z-plane from scan shown in C. (M and N) Fluorescent microscopy images of

805 LP14 lung tissue blocks. Red is SARS-CoV-2 anti-sera and blue is Hoechst nuclear stain. Scale

806 bars 100 μM (M) and 25 μM (N).

807

808 **Figure 3.** Male genital tract signal in LP14. (A, B, and C) PET/CT images highlighting the lower

809 abdomen of LP14 from the whole-body scan. Front (A) rotated 45° (B), and side (C) views are all

810 shown. Right and left labeled in front view. Red arrow in B and C shows location of baculum in

811 CT scan. (D and E) PET signal with CT overlay removed to highlight signal in MGT, front (D) and

812 side (E) views shown. (F, H, and J) Isolated 3D volume of MGT from whole body scan overlaid

813 with CT images. Side (F) rotated 45° (H), and front (J) views shown. (G, I, and K) Isolated 3D

814 volume of MGT used in overlays (F, H, and J) shown with same views. (L) Overlay of single z-

815 plane of PET signal from organ scan onto image of testis of LP14. (M) PET signal from single z-

816 plane of organ scan used in (L). (N) Image of LP14 testis used in (L). (O) 3D volume of PET signal

817 from organ scan of single testis in previous panels.

818

819   **Figure 4.** Immunofluorescence of LP14 Testes. (A) Fluorescent microscopy image of LP14

820   seminiferous tubules. ACE2 staining shown in red, Hoechst nuclear staining shown in blue. Inset

821   shows zoom in of single tubule to better view ACE2 staining in Sertoli and myeloid cells. Scale

822   bars 50 µM. (B) Fluorescent microscopy image of LP14 testis shows infected cells. SARS-CoV-2

823   anti-sera staining in green, background fluorescent in red, and Hoechst nuclear staining in blue.

824   Scale bars 25 µM. (C) Microscopy images of two tubules containing infected cells (top and

825   bottom rows). Red is SARS-CoV-2 anti-sera, green is smooth muscle actin, gold is vimentin, and

826   blue is Hoechst nuclear stain. Possible infected germ cells based on morphology and localization

827   and marked by arrow heads. Scale bars 20 µM.

828

829   **Figure 5.** IN22 PET/CT guided necropsy images. (A and B) Whole-body PET/CT scans of IN22

830   obtained 3-hours after probe administration. Front view (A) and side (B) both shown. (C and D)

831   Whole-body PET/CT scans of IN22 obtained 21-hours after probe administration. Front view (C)

832   and side (D) both shown. Right and left labeled in front views (A and C). (E) Organ tray post

833   necropsy and (F) PET/CT image. (G) Second organ tray post necropsy and (H) PET/CT image. (I)

834   Overlay of PET signal onto photograph of tissue cassettes.

835

836   **Figure 6.** IN22 lung pathology and PET signal. (A-D) Lung PET volumes were isolated and

837   overlaid on whole body CT scans. (A and B) Show lung volumes from 3-hour scan, side (A) and

838   front (B) views shown. (C and D) Show lung volumes from 21-hour scan, side (C) and front (D)

839   views shown. (E and F) Isolated lung PET volumes for each scan are shown independent of CT.

840   (G) Sagittal z-slice from CT showing lungs. (H) PET signal overlaid on z-slice from G. (I)

841   Transverse z-slice through torso from CT. (J) PET signal overlaid on z-slice from I. (K) Image of

842   respiratory tract after necropsy. (L) Inset showing overt lung pathology in right lower lobe. (M)

843   PET/CT signal from organ scan of respiratory tract. (N) PET/CT signal from M overlaid onto

844   image from K. (O) PET/CT signal with CT contrast increased to observe pathology in lower right

845   lung lobe. (P) H&E image of lung tissue showing areas of expanded alveolar space and

846   inflammatory infiltrate (arrows). (Q) Immunofluorescence image of the same tissue from P.

847   Green is SARS-CoV-2 anti-sera, red is background, and white is nuclear stain. White arrows

848   indicate SARS-CoV-2 positive cells. (R) H&E image of lung tissue showing macrophages and

849   neutrophils (arrowheads) and type II pneumocytes (arrows). (S) Immunofluorescence image

850   showing infected cells of the alveoli (arrows) and lining the alveolar septa (arrowheads). Green

851   is SARS-CoV-2 anti-sera, red is background, white is nuclear stain. All scale bars are 100 µM. (T)

852   Fluorescent microscopy image of IN22 lung tissue. Spike shown in green, nucleocapsid shown in

853   red, background in white, and Hoechst nuclear stain in blue. Scale bar 100 µM. (U, Y, W)

854   Additional fluorescent microscopy images of lung tissue showing foci of infected cells. U and W

855   are shown in low magnification Y. Green is SARS-CoV-2 anti-sera and blue is Hoechst nuclear

856   stain. Scales bar 500 µM. (X-Z) Validation of dual antibody staining utilizing spectral imaging. (X)

857   shows microscopy of J2 antibody with RedX secondary and rabbit anti-NC monoclonal () and

858   Cy5 secondary. (Y) Shows area within green square in X. White arrows point to regions of

859   interest that are cell associated. Grey arrows indicate control regions of spectral evaluation.

860   The areas evaluated by spectral imaging in (Y) are color coded and match with the spectra

861   shown in (Z).

862

863 **Figure 7.** Male genital tract signal in IN22. (A and B) PET/CT images highlighting the lower

864 abdomen of IN22 obtained 3-hours after probe administration. Front view (A) and side (B) both

865 shown. (C and D) PET/CT images highlighting the lower abdomen of IN22 obtained 21-hours

866 after probe administration. Front view (C) and side (D) both shown. (E and F) Isolated 3D

867 volume of MGT from 3-hour scan overlaid with whole-body CT. Side (E) and front (F) views

868 shown. (G and H) Isolated 3D volume of MGT from 21-hour scan overlaid with whole-body CT.

869 Side (G) and front (H) views shown. (I and J) Whole-body CT images of lower abdomen, red

870 contours outline the testicles and spermatic cords. Front (I) and side (J) views shown. (K and L)

871 3D volume of MGT overlaid onto CT images from previous panels. (M) Image of testicles after

872 necropsy. (N) PET signal from organ scan of testicles. (O) Overlay of PET signal onto image from

873 panel M. (P) Overlay of PET signal onto CT signal from same scan. White asterisks mark location

874 of pampiniform plexus in all previous panels. (Q and R) Fluorescence microscopy of SARS-CoV-2

875 infected cells in testicular tissue from IN22. Red is SARS-CoV-2 spike, green is SARS-CoV-2

876 nucleocapsid, white is background, and blue is Hoechst nuclear stain. Insets show channels

877 independently, larger image is all channels merged. Scale bars 10 µM (S) Fluorescent

878 microscopy image of corpus cavernosum tissue from an uninfected animal showing ACE2

879 staining in red, background in green, and Hoechst nuclear staining in blue. Scale bar 100 µM (T)

880 Fluorescence microscopy of SARS-CoV-2 infected cells in penile tissue from IN22. White is

881 dsRNA antibody J2, red is SARS-CoV-2 nucleocapsid, green is background, and blue is Hoechst

882 nuclear stain. (U, V, and W) Show individual cells highlighted in T.

883

884 **Figure 8.** JF82 PET/CT images from week and week 2 necropsy scans. (A and B) Whole-body

885 PET/CT scan of JF82 from 1-week post-infection. Front view (A) and side (B) both shown. (C and

886 D) Whole-body PET/CT scans of JF82 2-weeks post infection. Front view (C) and side (D) both

887 shown. Right and left labeled in front views (A and C). (E and F) Overlay of the week 1 scan

888 (shown in red) and the week 2 scan (shown in blue). Front (E) and side (F) views both shown.

889 (G) Organ tray post necropsy and (H) PET/CT image. (I) Second organ tray post necropsy and (J)

890 PET/CT image. (K) Overlay of PET signal onto photograph of tissue cassettes.

891

892 **Figure 9.** JF82 lung pathology and PET signal from two timepoints. (A-D) Lung PET volumes were

893 isolated and overlaid on whole body CT scans. (A and B) Show lung volumes from 1-wee scan,

894 side (A) and front (B) views shown. White asterisk indicates location of lung pathology

895 highlighted below. (C and D) Show lung volumes from 2-week scan, side (C) and front (D) views

896 shown. (E and F) Isolated lung PET volumes for each scan are shown independent of CT. (G and

897 H) Overlay of single z-image of PET signal onto single z-image of CT in the lungs at week 1 (G)

898 and week 2 (H). (I and J) Single z-image of CT used in G and H shown independent of PET signal

899 for week 1 (I) and week 2 (J). (K) Overlay of week 1 (shown in red) and week 2 (shown in blue)

900 PET signal. (L) Overlay from K shown with CT image to localize PET signal. Insets above show,

901 CT, week 1, and week 2 signal from left to right. White asterisk indicates location of left lung

902 pathology in all panels.

903

904 **Figure 10.** Male genital tract signal in JF82. (A and B) Front view PET/CT images highlighting the

905 lower abdomen of JF82 at 1-week (A) and 2-weeks (B). (C) Overlay of week 1 (shown in red) and

43

906   week 2 (shown in blue) PET signal. (D and E) Side view of same images shown in A and B. (F)

907   side view of overlay shown in C. (G and H) Isolated MGT volume from week 1 scan. Back (G) and

908   side (H) views shown. (I and J) Isolated MGT volume from week 2 scan. Back (I) and side (J)

909   views shown. (K, L, and M) Isolated MGT volume from week 2 with isolated penile and

910   testicular signal. Back (K), rotated 45° (L), and side (M) views shown. (N) H&E stain of JF82

911   testicular tissue. Degenerate seminiferous tubules highlighted in black oval. Scale bar 500 μM.

912   (O) Fluorescent microscopy shows a similar area of degenerate tubules. Green is CD206, red

913   caspase 3, and white nuclear stain. Scale bar 500 μM. (P) Higher magnification image of

914   degenerate tubules. Intraluminal macrophages (arrowheads) and Sertoli cells (arrows) are

915   shown inside tubules. Scale bar 50 μM (Q) Higher magnification of image in O shows Sertoli

916   cells (arrow) staining with caspase 3 and macrophages (arrowhead) staining with CD206. Scale

917   bar 50 μM. (R) Fluorescent microscopy image showing degenerate tubule full of intraluminal

918   macrophages. Red is caspase 3, green is CD206, and blue is nuclear stain. Scale bar 50 μM. (S)

919   Lower magnification microscopy image of degenerate and healthy tubules. Red is caspase 3,

920   green is CD206, and blue is nuclear stain. Scale bar 200 μM. (T and U) Fluorescent microscopy

921   images of infected cells in testicular tissue of JF82. White is SARS-CoV-2 anti-sera, red is NSP8,

922   green is nucleocapsid, and blue is Hoechst nuclear stain. Insets show individual channels, larger

923   image is merge. Scale bars 10 μM.

924

925   **Figure 11.** Comparison of SUVs across animals and timepoints. (A-D) Complete rotation series of

926   lung PET volumes for LP14 (A), IN22 (B), JF82 week 1 (C), and JF82 week 2 (D). (E-H) Front,

927   rotated 45°, and side views of MGT PET volumes for LP14 (E), IN22 (F), JF82 week 1 (G), and

928   JF82 week 2 (H). (I-K) Front and side views of whole-body scans, white lines indicate volumes

929   taken for heart and lungs for LP14 (I), IN22 (J), and JF82 week 1 (K). Insets show each image

930   without white outlines. (L) Total SUVs for whole-body scans and each individual volume isolated

931   displayed in graph. Animals are indicated by icon shape and volumes by color.

932

933   **Figure 12.** Comparison of prostate and penile signal between animals. (A-F) PET/CT signal in

934   lower abdomen for each animal at 1-week post-infection. LP14 front (A) and rotated 45° (B),

935   IN22 front (C) and rotated 45° (D), JF82 front (E) and rotated 45° (F). Asterisks mark location of

936   prostate. Insets show sagittal z-slice of each animal highlighting prostate signal (white circle).

937   (G-I) PET/CT volume of penis for IN22. Front (G) rotated 45° (H), and side (I) views shown. (J-L)

938   PET/CT volume of penis for JF82 at 2-weeks post-infection. Front (J) rotated 45° (K), and side (L)

939   views shown. (M) PET/CT signal of IN22 penis after necropsy. (N) PET/CT signal of JF82 penis

940   after necropsy. (O) PET/CT signal overlaid onto an image of tissue cassettes (P) containing

941   penile tissue of IN22. (Q) PET/CT signal overlaid onto an image of tissue cassettes (R) containing

942   penile tissue of JF82. (S-U) H&E images of testicular tissue from each animal. LP14 (S) and IN22

943   (T) shows normal spermatogenesis and tissue architecture. IN22 (U) shows degenerate tubules

944   (asterisks) interspersed among healthy tubules. Scale bars all 500 μM.

945

946   **Figure 13.** PET signal associated with the pampiniform plexus. (A) Labeled dissection showing

947   anatomical structure of a macaque testis. (B) CT image of testes and associated image showing

948   the matching anatomical features of the spermatic cord. (C) Inset highlighting the location and

949   appearance of the pampiniform plexus. White asterisks mark the vas deferens in all images. (D-

950   F) Single z PET/CT images of IN22 highlighting the PET signal associated with the pampiniform

951   plexus (yellow volume) from the frontal (D), sagittal (E), and transverse (F) plane. (G) CT image

952   used in E to highlight signal associated with pampiniform plexus (yellow volume). (H-L) Isolated

953   3D volumes of MGT PET signal shown from the front for IN22 (H), JF82 (J), and LP14 (L). White

954   circles outline testes. (I, K, M) Volumes from H, J, and L rotated 45°. (N) Sagittal z-slice of PET/CT

955   of LP14 showing right testis. (O) Frontal z-slice of PET/CT, colored lines correspond to sagittal

956   slices shown in N, P, and R. (P) Sagittal z-slice of PET/CT showing penile tissue. (Q) Frontal z-slice

957   highlighting the testicular tissue in white ovals. (R) Sagittal z-slice of PET/CT showing left testis

958   of LP14. White ovals highlight signal associated with testes and not pampiniform plexus.

959

960   **Figure 14.** Principle components analysis of SUV measures. (A) Mean SUV values from isolated

961   tissue volumes. (B) The ratio of total SUV for each tissue volume to whole-body total SUV. (C)

962   Heat map showing clustering of tissues and parameters measured from the PET data. (D)

963

964   **REFERENCES**

965   1.   Cheung CCL, Goh D, Lim X, Tien TZ, Lim JCT, Lee JN, Tan B, Tay ZEA, Wan WY, Chen EX,
966   Nerurkar SN, Loong S, Cheow PC, Chan CY, Koh YX, Tan TT, Kalimuddin S, Tai WMD, Ng JL, Low
967   JG-H, Yeong J, Lim KH. Residual SARS-CoV-2 viral antigens detected in GI and hepatic tissues
968   from five recovered patients with COVID-19. Gut. 2021. doi: 10.1136/GUTJNL-2021-324280.
969   2.   Kariyawasam JC, Jayarajah U, Riza R, Abeysuriya V, Seneviratne SL. Gastrointestinal
970   manifestations in COVID-19. Trans R Soc Trop Med Hyg. 2021;115(12):1362-88. doi:
971   10.1093/trstmh/trab042. PubMed PMID: 33728439; PMCID: PMC7989191.
972   3.   Keshavarz P, Rafiee F, Kavandi H, Goudarzi S, Heidari F, Gholamrezanezhad A. Ischemic
973   gastrointestinal complications of COVID-19: a systematic review on imaging presentation. Clin
974   Imaging. 2021;73:86-95. Epub 20201208. doi: 10.1016/j.clinimag.2020.11.054. PubMed PMID:
975   33341452; PMCID: PMC7837247.
976   4.   Javadekar NS. Gut in COVID 19-is it worth noticing. Ind Psychiatry J. 2021;30(Suppl
977   1):S267-S9. Epub 20211022. doi: 10.4103/0972-6748.328826. PubMed PMID: 34908706;
978   PMCID: PMC8611584.

979   5.   Paterson BJ, Durrheim DN. Wastewater surveillance: an effective and adaptable
980   surveillance tool in settings with a low prevalence of COVID-19. Lancet Planet Health.
981   2022;6(2):e87-e8. doi: 10.1016/S2542-5196(22)00009-2. PubMed PMID: 35150632; PMCID:
982   PMC8828367.
983   6.   Gregory DA, Wieberg CG, Wenzel J, Lin CH, Johnson MC. Monitoring SARS-CoV-2
984   Populations in Wastewater by Amplicon Sequencing and Using the Novel Program SAM Refiner.
985   Viruses. 2021;13(8). Epub 20210819. doi: 10.3390/v13081647. PubMed PMID: 34452511;
986   PMCID: PMC8402658.
987   7.   Nakamura Y, Katano H, Nakajima N, Sato Y, Suzuki T, Sekizuka T, Kuroda M, Izutani Y,
988   Morimoto S, Maruyama J, Koie M, Kitamura T, Ishikura H. SARS-CoV-2 is localized in
989   cardiomyocytes: a postmortem biopsy case. Int J Infect Dis. 2021;111:43-6. Epub 20210809. doi:
990   10.1016/j.ijid.2021.08.015. PubMed PMID: 34384897; PMCID: PMC8351278.
991   8.   Lei J, Liu Y, Xie T, Yao G, Wang G, Diao B, Song J. Evidence for residual SARS-CoV-2 in
992   glioblastoma tissue of a convalescent patient. Neuroreport. 2021;32(9):771-5. doi:
993   10.1097/WNR.0000000000001654. PubMed PMID: 33994523.
994   9.   Song E, Zhang C, Israelow B, Lu-Culligan A, Prado AV, Skriabine S, Lu P, Weizman OE, Liu
995   F, Dai Y, Szigeti-Buck K, Yasumoto Y, Wang G, Castaldi C, Heltke J, Ng E, Wheeler J, Alfajaro MM,
996   Levavasseur E, Fontes B, Ravindra NG, Van Dijk D, Mane S, Gunel M, Ring A, Kazmi SAJ, Zhang K,
997   Wilen CB, Horvath TL, Plu I, Haik S, Thomas JL, Louvi A, Farhadian SF, Huttner A, Seilhean D,
998   Renier N, Bilguvar K, Iwasaki A. Neuroinvasion of SARS-CoV-2 in human and mouse brain. J Exp
999   Med. 2021;218(3). doi: 10.1084/jem.20202135. PubMed PMID: 33433624; PMCID:
1000   PMC7808299.
1001   10.   Hanley B, Naresh KN, Roufosse C, Nicholson AG, Weir J, Cooke GS, Thursz M, Manousou
1002   P, Corbett R, Goldin R, Al-Sarraj S, Abdolrasouli A, Swann OC, Baillon L, Penn R, Barclay WS,
1003   Viola P, Osborn M. Histopathological findings and viral tropism in UK patients with severe fatal
1004   COVID-19: a post-mortem study. Lancet Microbe. 2020;1(6):e245-e53. Epub 20200820. doi:
1005   10.1016/S2666-5247(20)30115-4. PubMed PMID: 32844161; PMCID: PMC7440861.
1006   11.   Edenfield RC, Easley CAt. Implications of testicular ACE2 and the renin-angiotensin
1007   system for SARS-CoV-2 on testis function. Nat Rev Urol. 2022;19(2):116-27. Epub 20211126.
1008   doi: 10.1038/s41585-021-00542-5. PubMed PMID: 34837081; PMCID: PMC8622117.
1009   12.   Collins AB, Zhao L, Zhu Z, Givens NT, Bai Q, Wakefield MR, Fang Y. Impact of COVID-19
1010   on Male Fertility. Urology. 2022. doi: 10.1016/J.UROLOGY.2021.12.025.
1011   13.   Parker AM, Brigham E, Connolly B, McPeake J, Agranovich AV, Kenes MT, Casey K,
1012   Reynolds C, Schmidt KFR, Kim SY, Kaplin A, Sevin CM, Brodsky MB, Turnbull AE. Addressing the
1013   post-acute sequelae of SARS-CoV-2 infection: a multidisciplinary model of care. Lancet Respir
1014   Med. 2021;9(11):1328-41. Epub 20211019. doi: 10.1016/S2213-2600(21)00385-4. PubMed
1015   PMID: 34678213; PMCID: PMC8525917.
1016   14.   Zhao JM, Zhou GD, Sun YL, Wang SS, Yang JF, Meng EH, Pan D, Li WS, Zhou XS, Wang YD,
1017   Lu JY, Li N, Wang DW, Zhou BC, Zhang TH. [Clinical pathology and pathogenesis of severe acute
1018   respiratory syndrome]. Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi. 2003;17(3):217-21.
1019   PubMed PMID: 15340561.
1020   15.   Xu J, Qi L, Chi X, Yang J, Wei X, Gong E, Peh S, Gu J. Orchitis: a complication of severe
1021   acute respiratory syndrome (SARS). Biol Reprod. 2006;74(2):410-6. Epub 20051019. doi:
1022   10.1095/biolreprod.105.044776. PubMed PMID: 16237152; PMCID: PMC7109827.

1023   16.   Beddingfield BJ, Maness NJ, Fears AC, Rappaport J, Aye PP, Russell-Lodrigue K, Doyle-
1024   Meyers LA, Blair RV, Carias AM, Madden PJ, Redondo RL, Gao H, Montefiori D, Hope TJ, Roy CJ.
1025   Effective prophylaxis of COVID-19 in rhesus macaques using a combination of two parentally-
1026   administered SARS-CoV-2 neutralizing antibodies. bioRxiv. 2021:2021.05.26.445878-
1027   2021.05.26. doi: 10.1101/2021.05.26.445878.
1028   17.   Blair RV, Vaccari M, Doyle-Meyers LA, Roy CJ, Russell-Lodrigue K, Fahlberg M, Monjure
1029   CJ, Beddingfield B, Plante KS, Plante JA, Weaver SC, Qin X, Midkiff CC, Lehmicke G, Golden N,
1030   Threeton B, Penney T, Allers C, Barnes MB, Pattison M, Datta PK, Maness NJ, Birnbaum A,
1031   Fischer T, Bohm RP, Rappaport J. Acute Respiratory Distress in Aged, SARS-CoV-2–Infected
1032   African Green Monkeys but Not Rhesus Macaques. The American Journal of Pathology.
1033   2021;191(2):274-82. doi: 10.1016/J.AJPATH.2020.10.016.
1034   18.   Chandrashekar A, Liu J, Martino AJ, McMahan K, Mercad NB, Peter L, Tostanosk LH, Yu J,
1035   Maliga Z, Nekorchuk M, Busman-Sahay K, Terry M, Wriji LM, Ducat S, Martine DR, Atyeo C,
1036   Fischinger S, Burk JS, Slei MD, Pessaint L, Van Ry A, Greenhouse J, Taylor T, Blade K, Cook A,
1037   Finneyfrock B, Brown R, Teow E, Velasco J, Zahn R, Wegmann F, Abbink P, Bondzi EA, Dagotto
1038   G, Gebr MS, He X, Jacob-Dolan C, Kordana N, Li Z, Lifto MA, Mahrokhia SH, Maxfiel LF,
1039   Nityanandam R, Nkolol JP, Schmid AG, Mille AD, Bari RS, Alter G, Sorge PK, Este JD, Andersen H,
1040   Lewi MG, Barou DH. SARS-CoV-2 infection protects against rechallenge in rhesus macaques.
1041   Science. 2020;369(6505):812-7. doi: 10.1126/SCIENCE.ABC4776.
1042   19.   Fahlberg MD, Blair RV, Doyle-Meyers LA, Midkiff CC, Zenere G, Russell-Lodrigue KE,
1043   Monjure CJ, Haupt EH, Penney TP, Lehmicke G, Threeton BM, Golden N, Datta PK, Roy CJ, Bohm
1044   RP, Maness NJ, Fischer T, Rappaport J, Vaccari M. Cellular events of acute, resolving or
1045   progressive COVID-19 in SARS-CoV-2 infected non-human primates. Nat Commun.
1046   2020;11(1):6078. Epub 20201127. doi: 10.1038/s41467-020-19967-4. PubMed PMID:
1047   33247138; PMCID: PMC7695721.
1048   20.   Blair RV, Vaccari M, Doyle-Meyers LA, Roy CJ, Russell-Lodrigue K, Fahlberg M, Monjure
1049   CJ, Beddingfield B, Plante KS, Plante JA, Weaver SC, Qin X, Midkiff CC, Lehmicke G, Golden N,
1050   Threeton B, Penney T, Allers C, Barnes MB, Pattison M, Datta PK, Maness NJ, Birnbaum A,
1051   Fischer T, Bohm RP, Rappaport J. Acute Respiratory Distress in Aged, SARS-CoV-2-Infected
1052   African Green Monkeys but Not Rhesus Macaques. Am J Pathol. 2021;191(2):274-82. Epub
1053   20201107. doi: 10.1016/j.ajpath.2020.10.016. PubMed PMID: 33171111; PMCID: PMC7648506.
1054   21.   Santangelo PJ, Rogers KA, Zurla C, Blanchard EL, Gumber S, Strait K, Connor-Stroud F,
1055   Schuster DM, Amancha PK, Hong JJ, Byrareddy SN, Hoxie JA, Vidakovic B, Ansari AA, Hunter E,
1056   Villinger F. Whole-body immunoPET reveals active SIV dynamics in viremic and antiretroviral
1057   therapy-treated macaques. Nat Methods. 2015;12(5):427-32. Epub 2015/03/10. doi:
1058   10.1038/nmeth.3320. PubMed PMID: 25751144; PMCID: PMC4425449.
1059   22.   Taylor RA, McRaven MD, Carias AM, Anderson MR, Matias E, Arainga M, Allen EJ, Rogers
1060   KA, Gupta S, Kulkarni V, Lakhashe S, Lorenzo-Redondo R, Thomas Y, Strickland A, Villinger FJ,
1061   Ruprecht RM, Hope TJ. Localization of infection in neonatal rhesus macaques after oral viral
1062   challenge. PLoS Pathog. 2021;17(11):e1009855. Epub 20211118. doi:
1063   10.1371/journal.ppat.1009855. PubMed PMID: 34793582; PMCID: PMC8639050.
1064   23.   Taylor RA, Xiao S, Carias AM, McRaven MD, Thakkar DN, Arainga M, Allen EJ, Rogers KA,
1065   Kumarapperuma SC, Gong S, Fought AJ, Anderson MR, Thomas Y, Schneider JR, Goins B, Fox P,
1066   Villinger FJ, Ruprecht RM, Hope TJ. PET/CT targeted tissue sampling reveals virus specific dIgA

1067 can alter the distribution and localization of HIV after rectal exposure. PLoS Pathog.
1068 2021;17(6):e1009632. Epub 20210601. doi: 10.1371/journal.ppat.1009632. PubMed PMID:
1069 34061907; PMCID: PMC8195437.
1070 24.   Madden PJ, Arif MS, Becker ME, McRaven MD, Carias AM, Lorenzo-Redondo R, Xiao S,
1071 Midkiff CC, Blair RV, Potter EL, Martin-Sancho L, Dodson A, Martinelli E, Todd JM, Villinger FJ,
1072 Chanda SK, Aye PP, Roy CJ, Roederer M, Lewis MG, Veazey RS, Hope TJ. Development of an In
1073 Vivo Probe to Track SARS-CoV-2 Infection in Rhesus Macaques. Front Immunol.
1074 2021;12:810047. Epub 20211224. doi: 10.3389/fimmu.2021.810047. PubMed PMID: 35003140;
1075 PMCID: PMC8739270.
1076 25.   Fahlberg MD, Blair RV, Doyle-Meyers LA, Midkiff CC, Zenere G, Russell-Lodrigue KE,
1077 Monjure CJ, Haupt EH, Penney TP, Lehmicke G, Threeton BM, Golden N, Datta PK, Roy CJ, Bohm
1078 RP, Maness NJ, Fischer T, Rappaport J, Vaccari M. Cellular events of acute, resolving or
1079 progressive COVID-19 in SARS-CoV-2 infected non-human primates. Nature Communications
1080 2020 11:1. 2020;11(1):1-14. doi: 10.1038/s41467-020-19967-4.
1081 26.   Gao G, Hu X, Zhou Y, Rao J, Zhang X, Peng Y, Zhao J, Yao Y, Liu K, Liang M, Liu H, Deng F,
1082 Xia H, Shan C, Yuan Z. Infection and pathogenesis of the Delta variant of SARS-CoV-2 in Rhesus
1083 macaque. Virologica Sinica. 2022. doi: 10.1016/j.virs.2022.02.001.
1084 27.   Nicolas N, Michel V, Bhushan S, Wahle E, Hayward S, Ludlow H, de Kretser DM, Loveland
1085 KL, Schuppe HC, Meinhardt A, Hedger MP, Fijak M. Testicular activin and follistatin levels are
1086 elevated during the course of experimental autoimmune epididymo-orchitis in mice. Sci Rep.
1087 2017;7:42391. Epub 20170213. doi: 10.1038/srep42391. PubMed PMID: 28205525; PMCID:
1088 PMC5304336.
1089 28.   Cardona-Maya W, Velilla PA, Montoya CJ, Cadavid A, Rugeles MT. In vitro human
1090 immunodeficiency virus and sperm cell interaction mediated by the mannose receptor. J
1091 Reprod Immunol. 2011;92(1-2):1-7. Epub 20111019. doi: 10.1016/j.jri.2011.09.002. PubMed
1092 PMID: 22015004.
1093 29.   Cardona-Maya W, Lopez-Herrera A, Velilla-Hernandez P, Rugeles MT, Cadavid AP. The
1094 role of mannose receptor on HIV-1 entry into human spermatozoa. Am J Reprod Immunol.
1095 2006;55(4):241-5. doi: 10.1111/j.1600-0897.2005.00340.x. PubMed PMID: 16533334.
1096 30.   Benoff S, Hurley I, Cooper GW, Mandel FS, Hershlag A, Scholl GM, Rosenfeld DL.
1097 Fertilization potential in vitro is correlated with head-specific mannose-ligand receptor
1098 expression, acrosome status and membrane cholesterol content. Hum Reprod.
1099 1993;8(12):2155-66. doi: 10.1093/oxfordjournals.humrep.a137997. PubMed PMID: 8150918.
1100 31.   Corbett KS, Flynn B, Foulds KE, Francica JR, Boyoglu-Barnum S, Werner AP, Flach B,
1101 O'Connell S, Bock KW, Minai M, Nagata BM, Andersen H, Martinez DR, Noe AT, Douek N,
1102 Donaldson MM, Nji NN, Alvarado GS, Edwards DK, Flebbe DR, Lamb E, Doria-Rose NA, Lin BC,
1103 Louder MK, O'Dell S, Schmidt SD, Phung E, Chang LA, Yap C, Todd J-PM, Pessaint L, Ry AV,
1104 Browne S, Greenhouse J, Putman-Taylor T, Strasbaugh A, Campbell T-A, Cook A, Dodson A,
1105 Steingrebe K, Shi W, Zhang Y, Abiona OM, Wang L, Pegu A, Yang ES, Leung K, Zhou T, Teng IT,
1106 Widge A, Gordon I, Novik L, Gillespie RA, Loomis RJ, Moliva JI, Stewart-Jones G, Himansu S, Kong
1107 W-P, Nason MC, Morabito KM, Ruckwardt TJ, Ledgerwood JE, Gaudinski MR, Kwong PD,
1108 Mascola JR, Carfi A, Lewis MG, Baric RS, McDermott A, Moore IN, Sullivan NJ, Roederer M,
1109 Seder RA, Graham BS. Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman

1110   Primates. https://doiorg/101056/NEJMoa2024671. 2020;383(16):1544-55. doi:
1111   10.1056/NEJMOA2024671.

1112   32.   Lindsay KE, Bhosle SM, Zurla C, Beyersdorf J, Rogers KA, Vanover D, Xiao P, Araínga M,
1113   Shirreff LM, Pitard B, Baumhof P, Villinger F, Santangelo PJ. Visualization of early events in
1114   mRNA vaccine delivery in non-human primates via PET–CT and near-infrared imaging. Nature
1115   Biomedical Engineering 2019 3:5. 2019;3(5):371-80. doi: 10.1038/s41551-019-0378-3.

1116   33.   Soriano JB, Murthy S, Marshall JC, Relan P, Diaz JV, Condition WHOCCDWGoP-C-. A
1117   clinical case definition of post-COVID-19 condition by a Delphi consensus. Lancet Infect Dis.
1118   2021. Epub 20211221. doi: 10.1016/S1473-3099(21)00703-9. PubMed PMID: 34951953;
1119   PMCID: PMC8691845.

1120   34.   Ward H, Flower B, Garcia PJ, Ong SWX, Altmann DM, Delaney B, Smith N, Elliott P, Cooke
1121   G. Global surveillance, research, and collaboration needed to improve understanding and
1122   management of long COVID. Lancet. 2021;398(10316):2057-9. Epub 20211110. doi:
1123   10.1016/S0140-6736(21)02444-2. PubMed PMID: 34774190; PMCID: PMC8580495.

1124   35.   Duarte-Neto AN, Teixeira TA, Caldini EG, Kanamura CT, Gomes-Gouvea MS, Dos Santos
1125   ABG, Monteiro RAA, Pinho JRR, Mauad T, da Silva LFF, Saldiva PHN, Dolhnikoff M, Leite KRM,
1126   Hallak J. Testicular pathology in fatal COVID-19: A descriptive autopsy study. Andrology.
1127   2022;10(1):13-23. Epub 20210716. doi: 10.1111/andr.13073. PubMed PMID: 34196475; PMCID:
1128   PMC8444746.

1129   36.   Moghimi N, Eslami Farsani B, Ghadipasha M, Mahmoudiasl GR, Piryaei A, Aliaghaei A,
1130   Abdi S, Abbaszadeh HA, Abdollahifar MA, Forozesh M. COVID-19 disrupts spermatogenesis
1131   through the oxidative stress pathway following induction of apoptosis. Apoptosis. 2021;26(7-
1132   8):415-30. Epub 20210602. doi: 10.1007/s10495-021-01680-2. PubMed PMID: 34076792;
1133   PMCID: PMC8170653.

1134   37.   Yang M, Chen S, Huang B, Zhong JM, Su H, Chen YJ, Cao Q, Ma L, He J, Li XF, Li X, Zhou JJ,
1135   Fan J, Luo DJ, Chang XN, Arkun K, Zhou M, Nie X. Pathological Findings in the Testes of COVID-
1136   19 Patients: Clinical Implications. Eur Urol Focus. 2020;6(5):1124-9. Epub 20200531. doi:
1137   10.1016/j.euf.2020.05.009. PubMed PMID: 32563676; PMCID: PMC7261470.

1138   38.   Peirouvi T, Aliaghaei A, Eslami Farsani B, Ziaeipour S, Ebrahimi V, Forozesh M,
1139   Ghadipasha M, Mahmoudiasl GR, Aryan A, Moghimi N, Abdi S, Raoofi A, Kargar Godaneh M,
1140   Abdollahifar MA. COVID-19 disrupts the blood-testis barrier through the induction of
1141   inflammatory cytokines and disruption of junctional proteins. Inflamm Res. 2021;70(10-
1142   12):1165-75. Epub 20210826. doi: 10.1007/s00011-021-01497-4. PubMed PMID: 34436630;
1143   PMCID: PMC8387554.

1144   39.   Achua JK, Chu KY, Ibrahim E, Khodamoradi K, Delma KS, Iakymenko OA, Kryvenko ON,
1145   Arora H, Ramasamy R. Histopathology and Ultrastructural Findings of Fatal COVID-19 Infections
1146   on Testis. World J Mens Health. 2021;39(1):65-74. Epub 20201103. doi: 10.5534/wjmh.200170.
1147   PubMed PMID: 33151050; PMCID: PMC7752514.

1148   40.   Ma X, Guan C, Chen R, Wang Y, Feng S, Wang R, Qu G, Zhao S, Wang F, Wang X, Zhang D,
1149   Liu L, Liao A, Yuan S. Pathological and molecular examinations of postmortem testis biopsies
1150   reveal SARS-CoV-2 infection in the testis and spermatogenesis damage in COVID-19 patients.
1151   Cellular and Molecular Immunology. 2021;18(2):487-9. doi: 10.1038/s41423-020-00604-5.

41.   Ardestani Zadeh A, Arab D. COVID-19 and male reproductive system: pathogenic features and possible mechanisms. J Mol Histol. 2021;52(5):869-78. Epub 20210707. doi: 10.1007/s10735-021-10003-3. PubMed PMID: 34232425; PMCID: PMC8260577.

42.   Liu X, Chen Y, Tang W, Zhang L, Chen W, Yan Z, Yuan P, Yang M, Kong S, Yan L, Qiao J. Single-cell transcriptome analysis of the novel coronavirus (SARS-CoV-2) associated gene ACE2 expression in normal and non-obstructive azoospermia (NOA) human male testes. Sci China Life Sci. 2020;63(7):1006-15. Epub 20200430. doi: 10.1007/s11427-020-1705-0. PubMed PMID: 32361911; PMCID: PMC7195615.

43.   Li X, Lu H, Li F, Zhang Q, Wang T, Qiang L, Yang Q. Impacts of COVID-19 and SARS-CoV-2 on male reproductive function: a systematic review and meta-analysis protocol. BMJ Open. 2022;12(1):e053051. Epub 20220105. doi: 10.1136/bmjopen-2021-053051. PubMed PMID: 34987042.

44.   Li C, Ye Z, Zhang AJ, Chan JF, Song W, Liu F, Chen Y, Kwan MY, Lee AC, Zhao Y, Wong BH, Yip CC, Cai JP, Lung DC, Sridhar S, Jin D, Chu H, To KK, Yuen KY. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections by intranasal or testicular inoculation induces testicular damage preventable by vaccination in golden Syrian hamsters. Clin Infect Dis. 2022. Epub 20220218. doi: 10.1093/cid/ciac142. PubMed PMID: 35178548.

45.   Campos RK, Camargos VN, Azar SR, Haines CA, Eyzaguirre EJ, Rossi SL. SARS-CoV-2 Infects Hamster Testes. Microorganisms. 2021;9(6). Epub 20210617. doi: 10.3390/microorganisms9061318. PubMed PMID: 34204370; PMCID: PMC8235703.

46.   Ullah I, Prevost J, Ladinsky MS, Stone H, Lu M, Anand SP, Beaudoin-Bussieres G, Symmes K, Benlarbi M, Ding S, Gasser R, Fink C, Chen Y, Tauzin A, Goyette G, Bourassa C, Medjahed H, Mack M, Chung K, Wilen CB, Dekaban GA, Dikeakos JD, Bruce EA, Kaufmann DE, Stamatatos L, McGuire AT, Richard J, Pazgier M, Bjorkman PJ, Mothes W, Finzi A, Kumar P, Uchil PD. Live imaging of SARS-CoV-2 infection in mice reveals that neutralizing antibodies require Fc function for optimal efficacy. Immunity. 2021;54(9):2143-58 e15. Epub 20210818. doi: 10.1016/j.immuni.2021.08.015. PubMed PMID: 34453881; PMCID: PMC8372518.

47.   Pike JFW, Polley EL, Pritchett DY, Lal A, Wynia BA, Roudebush WE, Chosed RJ. Comparative analysis of viral infection outcomes in human seminal fluid from prior viral epidemics and Sars-CoV-2 may offer trends for viral sexual transmissibility and long-term reproductive health implications. Reprod Health. 2021;18(1):123. Epub 20210610. doi: 10.1186/s12978-021-01172-1. PubMed PMID: 34112171; PMCID: PMC8192109.

48.   Massarotti C, Garolla A, Maccarini E, Scaruffi P, Stigliani S, Anserini P, Foresta C. SARS-CoV-2 in the semen: Where does it come from? Andrology. 2021;9(1):39-41. Epub 20200728. doi: 10.1111/andr.12839. PubMed PMID: 32533891; PMCID: PMC7323151.

49.   Haghpanah A, Masjedi F, Salehipour M, Hosseinpour A, Roozbeh J, Dehghani A. Is COVID-19 a risk factor for progression of benign prostatic hyperplasia and exacerbation of its related symptoms?: a systematic review. Prostate Cancer Prostatic Dis. 2021. Epub 20210518. doi: 10.1038/s41391-021-00388-3. PubMed PMID: 34007019; PMCID: PMC8129694.

50.   Stopsack KH, Mucci LA, Antonarakis ES, Nelson PS, Kantoff PW. TMPRSS2 and COVID-19: Serendipity or Opportunity for Intervention? Cancer Discov. 2020;10(6):779-82. Epub 20200410. doi: 10.1158/2159-8290.CD-20-0451. PubMed PMID: 32276929; PMCID: PMC7437472.

1195   51.   Gedeborg R, Styrke J, Loeb S, Garmo H, Stattin P. Androgen deprivation therapy and
1196   excess mortality in men with prostate cancer during the initial phase of the COVID-19
1197   pandemic. PLoS One. 2021;16(10):e0255966. Epub 20211007. doi:
1198   10.1371/journal.pone.0255966. PubMed PMID: 34618806; PMCID: PMC8496782.
1199   52.   Soumarova R, Boday A, Krhutova V, Janotova A, Dvorakova M, Jaluvkova E, Stursa M,
1200   Perkova H. Prognostic and predictive molecular biological markers in prostate cancer -
1201   significance of expression of genes PCA3 and TMPRSS2. Neoplasma. 2015;62(1):114-8. doi:
1202   10.4149/neo_2015_014. PubMed PMID: 25563374.
1203   53.   Bhowmick NA, Oft J, Dorff T, Pal S, Agarwal N, Figlin RA, Posadas EM, Freedland SJ, Gong
1204   J. COVID-19 and androgen-targeted therapy for prostate cancer patients. Endocr Relat Cancer.
1205   2020;27(9):R281-R92. doi: 10.1530/ERC-20-0165. PubMed PMID: 32508311; PMCID:
1206   PMC7546583.
1207   54.   Kazan O, Culpan M, Efiloglu O, Atis G, Yildirim A. The clinical impact of androgen
1208   deprivation therapy on SARS-CoV-2 infection rates and disease severity. Turk J Urol.
1209   2021;47(6):495-500. doi: 10.5152/tud.2021.21278. PubMed PMID: 35118968.
1210   55.   Cinislioglu AE, Demirdogen SO, Cinislioglu N, Altay MS, Sam E, Akkas F, Tor IH, Aydin HR,
1211   Karabulut I, Ozbey I. Variation of Serum PSA Levels in COVID-19 Infected Male Patients with
1212   Benign Prostatic Hyperplasia (BPH): A Prospective Cohort Studys. Urology. 2022;159:16-21.
1213   Epub 20211006. doi: 10.1016/j.urology.2021.09.016. PubMed PMID: 34626600; PMCID:
1214   PMC8493783.
1215   56.   Mohamed MS, Moulin TC, Schioth HB. Sex differences in COVID-19: the role of
1216   androgens in disease severity and progression. Endocrine. 2021;71(1):3-8. Epub 20201111. doi:
1217   10.1007/s12020-020-02536-6. PubMed PMID: 33179220; PMCID: PMC7657570.
1218   57.   Reddy R, Farber N, Kresch E, Seetharam D, Diaz P, Ramasamy R. SARS-CoV-2 in the
1219   Prostate: Immunohistochemical and Ultrastructural Studies. The World Journal of Men's Health.
1220   2021;40. doi: 10.5534/WJMH.210174.
1221   58.   Fraga-Silva RA, Costa-Fraga FP, Montecucco F, Sturny M, Faye Y, Mach F, Pelli G, Shenoy
1222   V, da Silva RF, Raizada MK, Santos RA, Stergiopulos N. Diminazene protects corpus cavernosum
1223   against hypercholesterolemia-induced injury. J Sex Med. 2015;12(2):289-302. Epub 20141120.
1224   doi: 10.1111/jsm.12757. PubMed PMID: 25411084.
1225   59.   Kresch E, Achua J, Saltzman R, Khodamoradi K, Arora H, Ibrahim E, Kryvenko ON, Wolff
1226   Almeida V, Firdaus F, Hare JM, Ramasamy R. COVID-19 Endothelial Dysfunction Can Cause
1227   Erectile Dysfunction: Histopathological, Immunohistochemical, and Ultrastructural Study of the
1228   Human Penis. World J Mens Health. 2021;39:2287-4208. doi: 10.5534/wjmh.210055.
1229   60.   Sansone A, Mollaioli D, Ciocca G, Colonnello E, Limoncin E, Balercia G, Jannini EA. "Mask
1230   up to keep it up": Preliminary evidence of the association between erectile dysfunction and
1231   COVID-19. Andrology. 2021;00:1-7. doi: 10.1111/andr.13003.
1232   61.   Dal Moro F, Vendramin I, Livi U. The war against the SARS-CoV2 infection: Is it better to
1233   fight or mitigate it? Med Hypotheses. 2020;143:110129. Epub 20200722. doi:
1234   10.1016/j.mehy.2020.110129. PubMed PMID: 32721814; PMCID: PMC7373683.
1235   62.   Mejri R, Mrad Dali K, Chaker K, Bibi M, Ben Rhouma S, Nouira Y. Venous thrombosis of
1236   the pampiniform plexus after coronavirus infection (COVID-19): A case report. Urol Case Rep.
1237   2021;39:101860. Epub 20210927. doi: 10.1016/j.eucr.2021.101860. PubMed PMID: 34603969;
1238   PMCID: PMC8475016.

1239 63.   Alshoabi SA, Haider KH, Mostafa MA, Hamid AM, Daqqaq TS. An unusual and atypical
1240 presentation of the novel coronavirus: A case report and brief review of the literature. J Taibah
1241 Univ Med Sci. 2021;16(4):637-42. Epub 20210412. doi: 10.1016/j.jtumed.2021.01.014. PubMed
1242 PMID: 33867909; PMCID: PMC8038890.
1243 64.   Whiteley MS, Abu-Bakr O, Holdstock JM. Testicular vein thrombosis mimicking
1244 epididymo-orchitis after suspected Covid-19 infection. SAGE Open Med Case Rep.
1245 2021;9:2050313X211022425. Epub 20210604. doi: 10.1177/2050313X211022425. PubMed
1246 PMID: 34158948; PMCID: PMC8182169.
1247 65.   La Marca A, Busani S, Donno V, Guaraldi G, Ligabue G, Girardis M. Testicular pain as an
1248 unusual presentation of COVID-19: a brief review of SARS-CoV-2 and the testis. Reprod Biomed
1249 Online. 2020;41(5):903-6. Epub 20200723. doi: 10.1016/j.rbmo.2020.07.017. PubMed PMID:
1250 32826162; PMCID: PMC7377719.
1251 66.   Li K, Liu X, Huang Y, Liu X, Song Q, Wang R. Evaluation of testicular spermatogenic
1252 function by ultrasound elastography in patients with varicocele-associated infertility. Am J
1253 Transl Res. 2021;13(8):9136-42. Epub 20210815. PubMed PMID: 34540028; PMCID:
1254 PMC8430184.
1255 67.   Mali WP, Arndt JW, Coolsaet BL, Kremer J, Oei HY. Haemodynamic aspects of left-sided
1256 varicocele and its association with so-called right-sided varicocele. Int J Androl. 1984;7(4):297-
1257 308. doi: 10.1111/j.1365-2605.1984.tb00787.x. PubMed PMID: 6096276.
1258 68.   Aitken RJ. COVID-19 and human spermatozoa—Potential risks for infertility and sexual
1259 transmission? Andrology. 2021;9(1):48-52. doi: 10.1111/andr.12859.
1260 69.   Gacci M, Coppi M, Baldi E, Sebastianelli A, Zaccaro C, Morselli S, Pecoraro A, Manera A,
1261 Nicoletti R, Liaci A, Bisegna C, Gemma L, Giancane S, Pollini S, Antonelli A, Lagi F, Marchiani S,
1262 Dabizzi S, Degl'Innocenti S, Annunziato F, Maggi M, Vignozzi L, Bartoloni A, Rossolini GM, Serni
1263 S. Semen impairment and occurrence of SARS-CoV-2 virus in semen after recovery from COVID-
1264 19. Human Reproduction. 2021;0(0):1-10. doi: 10.1093/humrep/deab026.
1265 70.   Sengupta P, Leisegang K, Agarwal A. The impact of COVID-19 on the male reproductive
1266 tract and fertility: A systematic review. Arab J Urol. 2021;19(3):423-36. Epub 20210809. doi:
1267 10.1080/2090598X.2021.1955554. PubMed PMID: 34552795; PMCID: PMC8451696.
1268 71.   Li H, Xiao X, Zhang J, Zafar MI, Wu C, Long Y, Lu W, Pan F, Meng T, Zhao K, Zhou L, Shen
1269 S, Liu L, Liu Q, Xiong C. Impaired spermatogenesis in COVID-19 patients. EClinicalMedicine.
1270 2020;28. doi: 10.1016/j.eclinm.2020.100604.
1271 72.   Delli Muti N, Finocchi F, Tossetta G, Salvio G, Cutini M, Marzioni D, Balercia G. Could
1272 SARS-CoV-2 infection affect male fertility and sexuality? APMIS. 2022. Epub 20220203. doi:
1273 10.1111/apm.13210. PubMed PMID: 35114008.
1274 73.   Wesselink AK, Hatch EE, Rothman KJ, Wang TR, Willis MD, Yland J, Crowe HM, Geller RJ,
1275 Willis SK, Perkins RB, Regan AK, Levinson J, Mikkelsen EM, Wise LA. A prospective cohort study
1276 of COVID-19 vaccination, SARS-CoV-2 infection, and fertility. Am J Epidemiol. 2022. Epub
1277 20220120. doi: 10.1093/aje/kwac011. PubMed PMID: 35051292; PMCID: PMC8807200.
1278 74.   Xu J, Qi L, Chi X, Yang J, Wei X, Gong E, Peh S, Gu J. Orchitis: A Complication of Severe
1279 Acute Respiratory Syndrome (SARS). Biology of Reproduction. 2006;74(2):410-6. doi:
1280 10.1095/BIOLREPROD.105.044776.

1281 75.   Delle Fave RF, Polisini G, Giglioni G, Parlavecchio A, Dell'Atti L, Galosi AB. COVID-19 and
1282 male fertility: Taking stock of one year after the outbreak began. Archivio Italiano di Urologia e
1283 Andrologia. 2021;93(1):115-9. doi: 10.4081/aiua.2021.1.115.
1284 76.   Al-Kuraishy HM, Al-Gareeb AI, Faidah H, Alexiou A, Batiha GE. Testosterone in COVID-19:
1285 An Adversary Bane or Comrade Boon. Front Cell Infect Microbiol. 2021;11:666987. Epub
1286 20210908. doi: 10.3389/fcimb.2021.666987. PubMed PMID: 34568081; PMCID: PMC8455954.
1287 77.   Haghpanah A, Masjedi F, Alborzi S, Hosseinpour A, Dehghani A, Malekmakan L, Roozbeh
1288 J. Potential mechanisms of SARS-CoV-2 action on male gonadal function and fertility: Current
1289 status and future prospects. Andrologia. 2021;53(1):e13883-e. doi: 10.1111/and.13883.
1290 78.   Enikeev D, Taratkin M, Morozov A, Petov V, Korolev D, Shpikina A, Spivak L, Kharlamova
1291 S, Shchedrina I, Mestnikov O, Fiev D, Ganzha T, Geladze M, Mambetova A, Kogan E, Zharkov N,
1292 Demyashkin G, Shariat SF, Glybochko P. Prospective two-arm study of the testicular function in
1293 patients with COVID-19. Andrology. 2022. Epub 20220206. doi: 10.1111/andr.13159. PubMed
1294 PMID: 35124885.
1295

Figure 1. Study design and viral analysis of infected macaques. (A) Workflow of PET/CT guided necropsy. (B) Schematic showing the study design of probe administration, PET/CT scans, and infection. (C-E) Lung lesions were consistent with prior findings in NHPs infected with SARS-CoV-2 and varied from minimal in LP14 (C), moderate in IN22 (D), and mild in JF82 (E). Insets demonstrate the inflammatory infiltrate and in IN22 and JF82, type II pneumocyte hyperplasia (arrows). (F and G) Viral load measurements for all three animals. (F) shows copies/swab of genomic N while (G) shows copies/swab of subgenomic N.

48

Figure 2. LP14 PET/CT guided necropsy. (A and B) Whole-body PET/CT scans of LP14 8 days post-infection. Front view (A) and rotated 45° (B) both shown. PET signal is display as SUV. (C) Post necropsy PET/CT organ scan of LP14. (D and E) Images of tissues scanned in (C). (F) Overlay of PET signal onto photograph of small pieces of tissue in cassettes. (G and H) Lung PET signal was isolated and overlaid on whole body CT scans. Side (G) and front (H) view. (I and J) Isolated lung PET volumes used in G and H are shown independently, side view (I) and front view (J). (K and L) Single axial z-slice images of respiratory tract PET/CT signals are shown, each image represents a single z-plane from scan shown in C. (M and N) Fluorescent microscopy images of LP14 lung tissue blocks. Red is SARS-CoV-2 anti-sera and blue is Hoechst nuclear stain. Scale bars 100 µM (M) and 25 µM (N).

49

1179 **Figure 3. Male genital tract signal in LP14.** (A, B, and C) PET/CT images highlighting the lower
1180 abdomen of LP14 from the whole-body scan. Front (A), rotated 45° (B), and side (C) views are
1181 all shown. Right and left labeled in front view. Red arrow in B and C shows location of baculum
1182 in CT scan. (D and E) PET signal with CT overlay removed to highlight signal in MGT, front (D)
1183 and side (E) views shown. (F, H, and J) Isolated 3D volume of MGT from whole body scan
1184 overlaid with CT images. Side (F), rotated 45° (H), and front (J) views shown. (G, I, and K)
1185 Isolated 3D volume of MGT used in overlays (F, H, and J) shown with same views. (L) Overlay of
1186 single z-plane of PET signal from organ scan onto image of testis of LP14. (M) PET signal from
1187 single z-plane of organ scan used in (L). (N) Image of LP14 testis used in (L). (O) 3D volume of
1188 PET signal from organ scan of single testis in previous panels.
1189

Figure 4. Immunofluorescence of LP14 Testes. (A) Fluorescent microscopy image of LP14 seminiferous tubules. ACE2 staining shown in red, Hoechst nuclear staining shown in blue. Inset shows zoom in of single tubule to better view ACE2 staining in Sertoli and myoid cells. Scale bars 50 µM. (B) Fluorescent microscopy image of LP14 testis shows infected cells. SARS-CoV-2 anti-sera staining in green, background fluorescent in red, and Hoechst nuclear staining in blue. Scale bars 25 µM. (C) Microscopy images of two tubules containing infected cells (top and bottom rows). Red is SARS-CoV-2 anti-sera, green is smooth muscle actin, gold is vimentin, and blue is Hoechst nuclear stain. Possible infected germ cells marked by arrow heads. Scale bars 20 µM.

52

1201

1202
1203
1204

1205   **Figure 5. IN22 PET/CT guided necropsy images.** (A and B) Whole-body PET/CT scans of IN22
1206   obtained 3-hours after probe administration. Front view (A) and side (B) both shown. (C and D)
1207   Whole-body PET/CT scans of IN22 obtained 21-hours after probe administration. Front view (C)
1208   and side (D) both shown. Right and left labeled in front views (A and C). (E) Organ tray post
1209   necropsy and (F) PET/CT image. (G) Second organ tray post necropsy and (H) PET/CT image. (I)
1210   Overlay of PET signal onto photograph of tissue cassettes.
1211

1212

Figure 6. IN22 lung pathology and PET signal. (A-D) Lung PET volumes were isolated and overlaid on whole body CT scans. (A and B) Show lung volumes from 3-hour scan, side (A) and front (B) views shown. (C and D) Show lung volumes from 21-hour scan, side (C) and front (D) views shown. (E and F) Isolated lung PET volumes for each scan are shown independent of CT. (G) Sagittal z-slice from CT showing lungs. (H) PET signal overlaid on z-slice from G. (I)

1220   Transverse z-slice through torso from CT. (J) PET signal overlaid on z-slice from I. (K) Image of
1221   respiratory tract after necropsy. (L) Inset showing overt lung pathology in right lower lobe. (M)
1222   PET/CT signal from organ scan of respiratory tract. (N) PET/CT signal from M overlaid onto
1223   image from K. (O) PET/CT signal with CT contrast increased to observe pathology in lower right
1224   lung lobe. (P) H&E image of lung tissue showing areas of expanded alveolar space and
1225   inflammatory infiltrate (arrows). (Q) Immunofluorescence image of the same tissue from P.
1226   Green is SARS-CoV-2 anti-sera, red is background, and white is nuclear stain. White arrows
1227   indicate SARS-CoV-2 positive cells. (R) H&E image of lung tissue showing macrophages and
1228   neutrophils (arrowheads) and type II pneumocytes (arrows). (S) Immunofluorescence image
1229   showing infected cells of the alveoli (arrows) and lining the alveolar septa (arrowheads). Green
1230   is SARS-CoV-2 anti-sera, red is background, white is nuclear stain. All scale bars are 100 µM. (T)
1231   Fluorescent microscopy image of IN22 lung tissue. Spike shown in green, nucleocapsid shown in
1232   red, background in white, and Hoechst nuclear stain in blue. Scale bar 100 µM. (U, Y, W)
1233   Additional fluorescent microscopy images of lung tissue showing foci of infected cells. U and W
1234   are shown in low magnification Y. Green is SARS-CoV-2 anti-sera and blue is Hoechst nuclear
1235   stain. Scales bar 500 µM. (X-Z) Validation of dual antibody staining utilizing spectral imaging. (X)
1236   shows microscopy of J2 antibody with redX secondary and rabbit anti-NC monoclonal and Cy5
1237   secondary. (Y) Shows area within green square in X. White arrows point to regions of interest
1238   that are cell associated. Grey arrows indicate control regions of spectral evaluation. The areas
1239   evaluated by spectral imaging in (Y) are color coded and match with the spectra shown in (Z).

1240

1241
1242
Figure 7. Male genital tract signal of IN22. (A and B) PET/CT images highlighting the lower abdomen of IN22 obtained 3-hours after probe administration. Front view (A) and side (B) both shown. (C and D) PET/CT images highlighting the lower abdomen of IN22 obtained 21-hours after probe administration. Front view (C) and side (D) both shown. (E and F) Isolated 3D volume of MGT from 3-hour scan overlaid with whole-body CT. Side (E) and front (F) views

1248   shown. (G and H) Isolated 3D volume of MGT from 21-hour scan overlaid with whole-body CT.
1249   Side (G) and front (H) views shown. (I and J) Whole-body CT images of lower abdomen, red
1250   contours outline the testicles and spermatic cords. Front (I) and side (J) views shown. (K and L)
1251   3D volume of MGT overlaid onto CT images from previous panels. (M) Image of testicles after
1252   necropsy. (N) PET signal from organ scan of testicles. (O) Overlay of PET signal onto image from
1253   panel M. (P) Overlay of PET signal onto CT signal from same scan. White asterisks mark location
1254   of pampiniform plexus in all previous panels. (Q and R) Fluorescence microscopy of SARS-CoV-2
1255   infected cells in testicular tissue from IN22. Red is SARS-CoV-2 spike, green is SARS-CoV-2
1256   nucleocapsid, white is background, and blue is Hoechst nuclear stain. Insets show channels
1257   independently, larger image is all channels merged. Scale bars 10 μM (S) Fluorescent
1258   microscopy image of corpus cavernosum tissue from an uninfected animal showing ACE2
1259   staining in red, background in green, and Hoechst nuclear staining in blue. Scale bar 100 μM (T)
1260   Fluorescence microscopy of SARS-CoV-2 infected cells in penile tissue from IN22. White is
1261   dsRNA antibody J2, red is SARS-CoV-2 nucleocapsid, green is background, and blue is Hoechst
1262   nuclear stain. (U, V, and W) Show individual cells highlighted in T.
1263
1264
1265
1266
1267
1268
1269
1270
1271
1272
1273
1274
1275
1276
1277
1278
1279
1280
1281
1282
1283
1284
1285
1286
1287
1288
1289
1290
1291

Figure 8. JF82 PET/CT images from week and week 2 necropsy scans. (A and B) Whole-body PET/CT scan of JF82 from 1-week post-infection. Front view (A) and side (B) both shown. (C and D) Whole-body PET/CT scans of JF82 2-weeks post infection. Front view (C) and side (D) both shown. Right and left labeled in front views (A and C). (E and F) Overlay of the week 1 scan

1299   (shown in red) and the week 2 scan (shown in blue). Front (E) and side (F) views both shown.

1300   (G) Organ tray post necropsy and (H) PET/CT image. (I) Second organ tray post necropsy and (J)

1301   PET/CT image. (K) Overlay of PET signal onto photograph of tissue cassettes.

1302

1303

Figure 9. JF82 lung pathology and PET signal from two timepoints. (A-D) Lung PET volumes were isolated and overlaid on whole body CT scans. (A and B) Show lung volumes from 1-wee

1309   scan, side (A) and front (B) views shown. White asterisk indicates location of lung pathology
1310   highlighted below. (C and D) Show lung volumes from 2-week scan, side (C) and front (D) views
1311   shown. (E and F) Isolated lung PET volumes for each scan are shown independent of CT. (G and
1312   H) Overlay of single z-image of PET signal onto single z-image of CT in the lungs at week 1 (G)
1313   and week 2 (H). (I and J) Single z-image of CT used in G and H shown independent of PET signal
1314   for week 1 (I) and week 2 (J). (K) Overlay of week 1 (shown in red) and week 2 (shown in blue)
1315   PET signal. (L) Overlay from K shown with CT image to localize PET signal. Insets above show,
1316   CT, week 1, and week 2 signal from left to right. White asterisk indicates location of left lung
1317   pathology in all panels.
1318
1319
1320
1321
1322
1323
1324
1325
1326
1327
1328
1329
1330
1331
1332
1333
1334
1335
1336
1337
1338
1339
1340
1341
1342
1343
1344
1345
1346
1347
1348
1349
1350
1351
1352

1353

1354
1355
Figure 10. Male genital tract signal in JF82. (A and B) Front view PET/CT images highlighting the lower abdomen of JF82 at 1-week (A) and 2-weeks (B). (C) Overlay of week 1 (shown in red) and week 2 (shown in blue) PET signal. (D and E) Side view of same images shown in A and B. (F)

side view of overlay shown in C. (G and H) Isolated MGT volume from week 1 scan. Back (G) and side (H) views shown. (I and J) Isolated MGT volume from week 2 scan. Back (I) and side (J) views shown. (K, L, and M) Isolated MGT volume from week 2 with isolated penile and testicular signal. Back (K), rotated 45° (L), and side (M) views shown. (N) H&E stain of JF82 testicular tissue. Degenerate seminiferous tubules highlighted in black oval. Scale bar 500 µM. (O) Fluorescent microscopy shows a similar area of degenerate tubules. Green is CD206, red caspase 3, and white nuclear stain. Scale bar 500 µM. (P) Higher magnification image of degenerate tubules. Intraluminal macrophages (arrowheads) and Sertoli cells (arrows) are shown inside tubules. Scale bar 50 µM (Q) Higher magnification of image in O shows Sertoli cells (arrow) staining with caspase 3 and macrophages (arrowhead) staining with CD206. Scale bar 50 µM. (R) Fluorescent microscopy image showing degenerate tubule full of intraluminal macrophages. Red is caspase 3, green is CD206, and blue is nuclear stain. Scale bar 50 µM. (S) Lower magnification microscopy image of degenerate and healthy tubules. Red is caspase 3, green is CD206, and blue is nuclear stain. Scale bar 200 µM. (T and U) Fluorescent microscopy images of infected cells in testicular tissue of JF82. White is SARS-CoV-2 anti-sera, red is NSP8, green is nucleocapsid, and blue is Hoechst nuclear stain. Insets show individual channels, larger image is merge. Scale bars 10 µM.

1404 **Figure 11. Comparison of SUVs across animals and timepoints.** (A-D) Complete rotation series
1405 of lung PET volumes for LP14 (A), IN22 (B), JF82 week 1 (C), and JF82 week 2 (D). (E-H) Front,
1406 rotated 45°, and side views of MGT PET volumes for LP14 (E), IN22 (F), JF82 week 1 (G), and
1407 JF82 week 2 (H). (I-K) Front and side views of whole-body scans, white lines indicate volumes
1408 taken for heart and lungs for LP14 (I), IN22 (J), and JF82 week 1 (K). Insets show each image
1409 without white outlines. (L) Total SUVs for whole-body scans and each individual volume isolated
1410 displayed in graph. Animals are indicated by icon shape and volumes by color.
1411
1412

1413
1414

Figure 12. Comparison of prostate and penile signal between animals. (A-F) PET/CT signal in
lower abdomen for each animal at 1-week post-infection. LP14 front (A) and rotated 45° (B),

70

1417   IN22 front (C) and rotated 45° (D), JF82 front (E) and rotated 45° (F). Asterisks mark location of

1418   prostate. Insets show sagittal z-slice of each animal highlighting prostate signal (white circle).

1419   (G-I) PET/CT volume of penis for IN22. Front (G), rotated 45° (H), and side (I) views shown. (J-L)

1420   PET/CT volume of penis for JF82 at 2-weeks post-infection. Front (J), rotated 45° (K), and side (L)

1421   views shown. (M) PET/CT signal of IN22 penis after necropsy. (N) PET/CT signal of JF82 penis

1422   after necropsy. (O) PET/CT signal overlaid onto an image of tissue cassettes (P) containing

1423   penile tissue of IN22. (Q) PET/CT signal overlaid onto an image of tissue cassettes (R) containing

1424   penile tissue of JF82. (S-U) H&E images of testicular tissue from each animal. LP14 (S) and IN22

1425   (T) shows normal spermatogenesis and tissue architecture. IN22 (U) shows degenerate tubules

1426   (asterisks) interspersed among healthy tubules. Scale bars all 500 µM.

1427

Figure 13. PET signal associated with the pampiniform plexus. (A) Labeled dissection showing anatomical structure of a macaque testis. (B) CT image of testes and associated image showing the matching anatomical features of the spermatic cord. (C) Inset highlighting the location and

1433   appearance of the pampiniform plexus. White asterisks mark the vas deferens in all images. (D-

1434   F) Single z PET/CT images of IN22 highlighting the PET signal associated with the pampiniform

1435   plexus (yellow volume) from the frontal (D), sagittal (E), and transverse (F) plane. (G) CT image

1436   used in E to highlight signal associated with pampiniform plexus (yellow volume). (H-L) Isolated

1437   3D volumes of MGT PET signal shown from the front for IN22 (H), JF82 (J), and LP14 (L). White

1438   circles outline testes. (I, K, M) Volumes from H, J, and L rotated 45°. (N) Sagittal z-slice of PET/CT

1439   of LP14 showing right testis. (O) Frontal z-slice of PET/CT, colored lines correspond to sagittal

1440   slices shown in N, P, and R. (P) Sagittal z-slice of PET/CT showing penile tissue. (Q) Frontal z-slice

1441   highlighting the testicular tissue in white ovals. (R) Sagittal z-slice of PET/CT showing left testis

1442   of LP14. White ovals highlight signal associated with testes and not pampiniform plexus.

1443

Figure 14. Principle components analysis of SUV measures. (A) Mean SUV values from isolated tissue volumes. (B) The ratio of total SUV for each tissue volume to whole-body total SUV. (C) Heat map showing clustering of tissues and parameters measured from the PET data. (D)

1449   Principal components analysis of measures showing hierarchical clustering of tissues and
1450   measures.
1451